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Abstract  
The validation of an analytical method is a necessary step in controlling the quality of 
quantitative analysis. Method validation is an established process which provides 
documentary evidence that a system fulfils its pre-defined specification, or shows that an 
analytical method is acceptable for its intended purpose. The purpose of the present study 
was to develop and validate analytical procedures for the quantitative determination in 
surface water of substances selected in the first watch list. Two different methods were 
developed and validated:  
 a multi-residual method based on SPE-LC-MS/MS analysis, using OASIS HLB as 
sorbent material for the extraction of 1 litre water samples and quantitative 
determination of EE2, E2, E1, diclofenac, azithromycin, clarythromycin, methiocarb 
acetamiprid, clothianidin, imidacloprid, thiacloprid, thiametoxam and oxadiazon;  
 a multi-residual method based on LLE-GC-MS, using hexane as an extraction 
solvent for the extraction of 0.01 litre water samples and quantitative 
determination of BHT, EHMC and Triallate. 
 
The calibration curves, working ranges, recoveries, detection and quantification limits, 
trueness as well as repeatability were determined. The uncertainty budget was estimated 
based on in-house validation data.  
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1 Introduction 
The Commission Implementing Decision (EU) 2015/495 of 20 March 2015 established a 
first watch list of substances for EU-wide monitoring in the field of water policy pursuant 
to Directive 2008/105/EC of the European Parliament and of the Council.  
 
Up to 10 groups of substances have been selected for which EU-wide monitoring data are 
to be gathered for the purpose of supporting future prioritisation exercises in accordance 
with Article 16(2) of Directive 2000/60/EC of the European Parliament and of the Council.  
Ten substances/groups of substances have been selected for which EU-wide monitoring 
data are to be gathered for the purpose of supporting future prioritisation exercises in 
accordance with Article 16(2) of Directive 2000/60/EC of the European Parliament and of 
the Council. 
The substances are listed in Table 1. 
Table 1: Substances on the first watch list 
Name of 
substance 
CAS number 
EU 
number(*)  
Formula 
Maximum 
acceptable 
method 
detection 
limit (ng/l) 
17--
Ethinylestradiol 
(EE2) 
57-63-6 200-342-2 
 
0.035 
17--Estradiol (E2) 50-82-2, 200-023-8 
 
0.4 
Estrone (E1) 53-16-7 200-023-8 
 
0.4 
Diclofenac 15307-79-6 239-348-5 
 
10 
2.6-Ditert-butyl-4-
methylphenol (BHT) 
128-37-0 204-881-4 
 
3 160 
2-Ethylhexyl 4-
methoxycinnamate 
5466-77-3 226-775-7 
 
6 000 
Erythromycin 114-07-8 204-040-1 
 
90 
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Name of 
substance 
CAS number 
EU 
number(*)  
Formula 
Maximum 
acceptable 
method 
detection 
limit (ng/l) 
Clarythromycin 81103-11-9  
 
90 
Azythromycin 83905-01-5 617-500-5 
 
90 
Methiocarb 2032-65-7 217-991-2 
 
10 
Acetamiprid 
135410-20-7/ 
160430-64-8 
 
 
9 
Clothianidin 210880-92-5 433-460-1 
 
9 
Imidacloprid 
105827-78-9/ 
138261-41-3 
428-040-8 
 
9 
Thiacloprid 111988-49-9  
 
9 
Thiamethoxam 153719-23-4 428-650-4 
 
9 
Oxadiazon 19666-30-9 243-215-7 
 
88 
Triallate 2303-17-5 218-962-7 
 
670 
(*): European Union number not available for all substances. 
 
For each substance a maximum acceptable method detection limit (LOD), expressed as 
ng/l in whole water, was established which corresponded to the substance-specific 
predicted no-effect concentration (PNEC) in the relevant matrix. 
In accordance with (1) of the Commission Implementing Decision (EU) 2015/495 of 
20 March 2015, ‘the method detection limit should be at least as low as the substance-
specific PNEC for each substance in the relevant matrix. If new information leads to a 
Page 5 of 78 
decrease in the PNEC for particular substances, the maximum acceptable method 
detection limit might have to be lowered while those substances remain on the list. The 
analytical methods are not considered to entail excessive costs.’ 
In the methods validation described in this report, calibration ranges have been 
established which include PNEC values in the higher part of the curves in order to have 
the possibility to further lower the limit of detections. This could preserve the method 
validity and the collected datasets in case of future PNEC values decreases. 
This approach was not applicable for 17-ethynyl estradiol, because today's state-of-the-
art analytical techniques allow us to reach sensitivity levels just close to its PNEC 
(i.e. 0.035 ng/l).  
Considering the huge difference among PNEC values (and consequently among maximum 
acceptable method detection limits) and chemical and physical properties of the selected 
compounds, two different methods have been developed and validated:  
 a multi-residual method based on SPE-LC-MS/MS analysis, using OASIS HLB as
sorbent material for the extraction of 1 litre water samples and quantitative
determination of EE2, E2, E1, diclofenac, azithromycin, clarythromycin, methiocarb
acetamiprid, clothianidin, imidacloprid, thiacloprid, thiametoxam and oxadiazon.
Neither pH modification nor any other sample pre-treatment was performed in
order to allow the extraction of all the selected compounds;
 a multi-residual method based on LLE-GC-MS, using hexane as the extraction
solvent for the extraction of 0.01 litre water samples and quantitative
determination of BHT, EHMC and Triallate.
The present document consists of three sections: 
 experimental set-up of method validation and results;
 ‘Supplementary information’ specifying chemicals, laboratory equipment,
instrumental parameters and extraction procedures;
 ‘Annex 1’ statistical evaluation on experimental dataset.
2 Experimental set-up of methods validation 
Different experiments were carried out for the characterisation of the developed 
procedures in terms of linearity and working range, limit of detection and quantitation, 
recovery, trueness, repeatability, intermediate precision and uncertainty budget. 
In our approach, a calibration curve created from freshly prepared standards and quality 
control samples (QCs) in MilliQ water were run on five different days. Some of the 
experiments were used in the evaluation of different parameters.  
Specifications for all standard and sample solutions prepared and used for the method 
development are found in the section ‘Supplementary Information’.  
The analyte/internal standard peak area ratios were used as target parameters for 
quantitation. A weighted (1/c) least-square regression analysis of data was performed in 
order to determine the calibration curve parameters and the coefficient of determination 
(R2). 
The equation obtained with the linear regression method is as follows: 
X = 
A
BY 
where: 
X = analyte concentration 
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Y = peak area ratio = 
areapeak  I.S.
areapeak    analyte 
 
A = slope  
B = intercept. 
 
2.1 Selectivity 
Selectivity of quantitative determination was accomplished by relative retention times and 
by operating in multiple reaction monitoring (MRM) mode using LC-MS/MS and in selected 
ion monitoring (SIM) mode using GC-MS.  
At least two MRM transitions or two selected fragment ions were recorded for each 
compound. 
 
2.2 Limits of detection and quantification  
The limits of detection and quantification were estimated both in MilliQ and surface water 
by analysing blank samples belonging to the respective calibration curves. 
The mean value of blank samples (b) and the relative standard deviation (RSD) served for 
LOD and LOQ estimations, in accordance with the following equations: 
LOD = b + 3SD; 
LOQ = b + 10SD. 
Limits of quantification of the developed procedure should be at least as low as the 
maximum acceptable method detection limits stated in the Commission Implementing 
Decision (EU) 2015/495. 
 
2.3 Linearity study 
The calibration standards in MillliQ water (six different spiking levels, including a blank 
sample) were freshly prepared and processed on each day of validation. Table 2 indicates 
the covered calibration ranges and the level of internal standard used for analytical 
determination. 
Table 2: Studied calibration ranges  
Analyte 
Calibration standard Concentration (ng/l) Internal standard  
Conc (ng/l) E D C B A 
EE2 0.56 0.28 0.14 0.07 0.035 1 
E2 3.2 1.6 0.8 0.4 0.2 1 
E1 3.2 1.6 0.8 0.4 0.2 1 
Diclofenac 80 40 20 10 5 1.1 
BHT 6320 3160 1580 790 395 1800 
EHMC 12000 6000 3000 1500 750 2000 
Clarythromycin 180 90 45 22.5 11.25 1 
Azythromycin 180 90 45 22.5 11.25 1 
Methiocarb 20 10 5 2.5 1.25 1.1 
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Analyte 
Calibration standard Concentration (ng/l) Internal standard  
Conc (ng/l) E D C B A 
Acetamiprid 18.08 9.04 4.52 2.26 1.13 1.1 
Clothianidin 18.08 9.04 4.52 2.26 1.13 1.2 
Imidacloprid 18.08 9.04 4.52 2.26 1.13 1 
Thiacloprid 18.08 9.04 4.52 2.26 1.13 1.1 
Thiamethoxam 18.08 9.04 4.52 2.26 1.13 1.3 
Oxadiazon 176 88 44 22 11 1.1 
Triallate 1339.84 669.92 334.96 167.48 83.74 2000 
 
The relationship (goodness of fit) between peak area ratios of analyte/IS and 
concentrations in the concentration range investigated was assessed by the coefficient of 
determination (R2) and by the shape of the distribution of residuals around the horizontal 
axis. 
The acceptance criteria set for calibration curves were: 
 R2  0.9900 calculated over five calibration curves; and  
 random dispersion of residuals around the horizontal axis, proving the pertinence 
of the linear regression model to interpret the data. 
 
2.4 Matrix comparison 
In the determination of the 16 selected compounds in water samples, calibration curves 
prepared in MilliQ water were compared with those prepared in surface water (i.e. Ispra 
Bay, Varese, Italy). This comparison study was formulated to identify whether or not a 
significant matrix effect occurs for all or some of the analytes. 
For this purpose, five calibration curves in MilliQ water and three calibration curves in 
surface water were determined on five different days. Analysis of covariance (ANCOVA) 
was first used to compare the calibration curve within each water type to check the stability 
over several days. Calibrations were then compared between water types to assess 
whether a statistically significant change occurred in terms of slopes and intercepts. 
The ANCOVA is a statistical tool that can be used to compare regression curves (slopes 
and intercepts). The ANCOVA is an extension of the analysis of variance (ANOVA) that 
provides a means of statistically controlling the (linear) effect of one or more continuous 
variables that are not part of the main experimental manipulation but have an influence 
on the dependent variable (Field et al., 2012). These variables are called covariates and 
should be measured on an interval or ratio scale. A one-way ANCOVA evaluates whether 
population averages of the dependent variable are the same across all levels of a factor 
(independent variable), adjusting for differences in the covariate. The factor divides 
individuals into two or more groups or levels, while the covariate and the dependent 
variable differentiate individuals based on quantitative dimensions. The one-way ANCOVA 
is used to analyse data from several types of studies, including studies that investigate 
the differences among calibration curves in order to check their stability (2), evaluate 
comparison between matrix types (3), and to compare different measurement procedures 
(4). 
ANCOVA makes the same assumptions as ANOVA with two additional considerations 
(points 1 and 5): 
1. independence: the covariate variable is independent of the groups (i.e. the 
covariant and independent variables are independent); 
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2. normality: the residuals must be normally distributed around the regression line 
for each group; 
3. homogeneity of variance (homoscedasticity): the variance must be equal for both 
groups around their respective regression lines; 
4. linearity: the relationship between the dependent variable (y) and the covariate (x) 
is linear for each factor; 
5. homogeneity of regression slopes: the regression lines for these individual factors 
are assumed to be parallel (they have the same slope). 
 
2.5 Repeatability and intermediate precision 
Three QCs were freshly prepared in MilliQ water and analysed on three different occasions 
at two spiking levels for a total of 9 independent sample preparations. Table 3 summarises 
the spiking levels studied for each analyte. 
Table 3: Level of quality control samples 
Analyte 
QC concentration (ng/l) 
QC H QC L 
EE2 0.42 0.0525 
E2 2.4 0.3 
E1 2.4 0.3 
Diclofenac 60 7.5 
BHT 4500 450 
EHMC  9360 936 
Clarythromycin 135 16.9 
Azythromycin 135 16.9 
Methiocarb 15 1.9 
Methiocarb 15 1.9 
Acetamiprid 13.6 1.7 
Clothianidin 13.6 1.7 
Imidacloprid 13.6 1.7 
Thiacloprid 13.6 1.7 
Thiamethoxam 13.6 1.7 
Oxadiazon 132 16.5 
Triallate 100.8 1005 
 
The acceptance criterion for the RSD of the repeatability and intermediate precision was 
set to 30% at both spiking levels.  
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2.6 Extraction variability of trueness 
Due to the absence of Certified Reference Material (CRM) in the market, the trueness was 
evaluated as extraction variability of target analytes in spiked samples. The average 
concentrations found in spiked samples were compared to the added (theoretical) 
concentrations in order to estimate the extraction variability as slope of the regression 
line, expressed as a percentage. Values in the range 80-120 % were considered 
satisfactory. 
2.7 Recovery 
Recovery was evaluated by extracting and analysing in triplicate 1-litre MilliQ water 
samples spiked, before extraction, with native analytes only. The internal standard was 
then added to the extracts at the end of the sample preparation with the aim of allowing 
an estimation of analyte loss during processing. 
The recovery was evaluated by comparing the ratios analyte/IS in spiked samples to the 
same ratios obtained by analysing a standard solution containing native compounds and 
the labelled solution at the same concentration levels. 
The spiking levels studied for each analyte are reported in Table 4. 
Table 4: Spiking levels for recovery evaluation 
Analyte 
Spiking level for  
recovery evaluation (ng/l) 
EE2 
0.035 
10 
E2 
10 
0.035 
E1 
10 
0.035 
Diclofenac 11.6 
BHT 
450 
4500 
EHMC 
936 
9360 
Clarythromycin 10.4 
Azythromycin 10.2 
Methiocarb 11 
Acetamiprid 13.8 
Clothianidin 12.8 
Imidacloprid 10 
Thiacloprid 10.8 
Thiamethoxam 9.8 
Oxadiazon 12.2 
Triallate 
100.8 
1005 
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3 Validation procedure and results 
3.1 Selectivity 
3.1.1 LC-MS/MS 
For the identification of selected analytes, the two most abundant MRM transition ions 
from the precursor ion were chosen and monitored. The first was used for quantitation 
purposes, whereas the second (‘qualifier’) was used to confirm the presence of the target 
compound in the sample. The quantitated analyte was identified by comparing the 
retention time of the corresponding standard and the ratio between two ions recorded 
(± 30 %), in the standard and water samples. 
The selected mass transitions used for quantification and confirmation were reported in 
Table 27 and 28. 
3.1.2 GC-MS 
For the identification of BHT, EHMC and triallate, SIM was used and two selected ions 
among the most abundant were recorded, one for quantitation purposes and the other for 
confirmation. 
The quantitated analytes were identified by comparing the retention time of the 
corresponding standard and the presence of peak on both selected ions.  
The selected ions used for quantification and confirmation are reported in Table 30. 
3.2 Limit of detection (LOD) and limit of quantification (LOQ) 
Limits of detection and quantification were estimated by analysing blank samples in the 
respective matrix. 
The mean values of the blank samples (b) and standard deviation (SD) were calculated 
using the data output from these experiments. LOD and LOQ were estimated according to 
the formula reported in 2.3. 
The results of the LOD and LOQ estimation are shown in Table 5, both for MilliQ and surface 
water. 
Table 5: LOD and LOQ 
Matrix MilliQ water Surface water  
Analyte 
Nr of 
blanks 
analysed 
LOD 
(ng/l) 
LOQ 
(ng/l) 
Nr of 
blanks 
analysed 
LOD 
(ng/l) 
LOQ 
(ng/l) 
EE2 4 0.01 0.03 3 0.03 0.07 
E2 5 0.05 0.13 3 0.04 0.09 
E1 5 0.01 0.02 3 0.09 0.1 
Diclofenac 4 0.47 1.09 3 1 2.6 
BHT 5 21.53 42.64 3 19.6 39.6 
EHMC 5 25.48 60.57 3 30.4 69.1 
Clarythromycin 2 0.13 0.33 3 2.1 4.6 
Azythromycin 2 0.59 1.34 3 1.3 2.6 
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Matrix MilliQ water Surface water  
Analyte 
Nr of 
blanks 
analysed 
LOD 
(ng/l) 
LOQ 
(ng/l) 
Nr of 
blanks 
analysed 
LOD 
(ng/l) 
LOQ 
(ng/l) 
Methiocarb 4 0.07 0.17 3 0.01 0.02 
Acetamiprid 4 0.04 0.09 3 0.08 0.2 
Clothianidin 4 0.41 1.07 3 0.06 0.1 
Imidacloprid 5 0.11 0.27 3 0.5 1.0 
Thiacloprid 4 0.03 0.05 3 0.04 0.05 
Thiamethoxam 4 0.66 1.6 3 0.5 1 
Oxadiazon 4 0.2 0.4 3 0.4 1 
Triallate 5 15.41 31.60 3 22.9 49.2 
 
LODs and LOQs resulted to be below the established Maximum Detection Limits (MDLs) 
indicated in the Commission Implementing Decision (EU) 2015/495 both in case of MilliQ 
and surface water.  
However, special care is recommended when evaluating these methodological parameters 
in the presence of matrix components which could interfere with analytes determination.  
The overall sensitivity of developed procedure could be affected by the real matrix, even 
in cases where the regression analysis did not show any statistical difference.  
This contribution becomes even more crucial when the LOD and LOQ are strictly in the 
range of MDL, as it is clearly shown by EE2 analysis.  
LOD and LOQ were estimated to be 0.01 and 0.03ng/l in MilliQ water.  
EE2 analysis in surface water showed a baseline noise increase compared to MilliQ water. 
Consequently LOD and LOQ were estimated to be about 0.03 and 0.07ng/l, respectively, 
as showed in Figure 33 and 34.  
Nevertheless, the recommendations about MDL for this compound were fully met.  
As rule of thumb, a proper verification of sensitivity parameters using real matrix samples 
should always be performed to guarantee the reliability of produced datasets. 
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Figure 1: Chromatogram of EE2 extracted from 1 litre MilliQ water 
 
Figure 2: Chromatogram of EE2 extracted from 1 litre surface water 
 
3.3 Linearity study 
The linearity of the whole procedures in MilliQ water was studied in calibration ranges 
reported in Table 6. 
Table 6: Calibration ranges and maximum acceptable method detection limit (ng/l) 
Analyte 
Calibration 
range (ng/l) in 
MilliQ water 
Maximum acceptable 
method detection 
limit (ng/l) 
EE2 0.035-0.56 0.035 
E2 0.2-3.2 0.4 
E1 0.2-3.2 0.4 
Diclofenac 5-80 10 
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Analyte 
Calibration 
range (ng/l) in 
MilliQ water 
Maximum acceptable 
method detection 
limit (ng/l) 
BHT 375-6000 3160 
EHMC 780-12480 6000 
Clarythromycin 11.25-180 90 
Azythromycin 11.25-180 90 
Methiocarb 1.25-20 10 
Acetamiprid 1.13-18.08 9 
Clothianidin 1.13-18.08 9 
Imidacloprid 1.13-18.08 9 
Thiacloprid 1.13-18.08 9 
Thiamethoxam 1.13-18.08 9 
Oxadiazon 11-176 88 
Triallate 83.75-1340 670 
 
In order to verify the linearity of the calibration curve, a blank sample spiked only with 
labelled IS and five spiked MilliQ water samples were extracted and analysed on three 
different days. The calibration curves are illustrated in Figure 1. 
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Figure 3: EE2 calibration curve 
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Figure 4: E2 calibration curve 
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Figure 5: E1 calibration curve 
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Figure 6: Diclofenac calibration curves 
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Figure 7: BHT calibration curves 
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Figure 8: EHMC calibration curves 
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Figure 9: Azithromycin calibration curves 
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Figure 10: Clarithromycin calibration curves 
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Figure 11: Methiocarb calibration curves 
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Figure 12: Acetamiprid calibration curves 
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Figure 13: Clothianidin calibration curves 
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Figure 14: Imidacloprid calibration curves 
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Figure 15: Thiacloprid calibration curves 
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Figure 16: Thiamethoxam calibration curves 
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Figure 17: Oxadiazon calibration curves 
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Figure 18: Triallate calibration curves 
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Table 7 summarises the coefficients of determination on five days of validation, together 
with the mean values and the RSDs for each selected compound. 
Table 7: Coefficient of determination (R2) values for calibration curves on different days 
 
For all analytes, the R2 respect the set performance criteria of > 0.9900.
Analyte 
R2  
Day 1 
R2  
Day 2 
R2  
Day 3 
R2  
Day 4 
R2  
Day 5 
Mean 
R2 
RSD 
% 
EE2 0.9956 0.9820 0.9960 0.9870 0.9960 0.9913 0.6 
E2 0.9940 0.9970 0.9815 0.9987 0.9831 0.9921 0.8 
E1 0.9933 0.9992 0.9964 0.9976 0.9833 0.9939 0.7 
Diclofenac 0.9815 0.9939 0.9909 0.9992 0.9849 0.9987 0.6 
BHT 0.9978 0.9995 0.9975 0.9965 0.9997 0.9982 0.1 
EHMC 0.9887 0.9965 0.9715 0.9977 0.9953 0.9900 1.1 
Clarythromycin 0.9937 0.9900 0.9950 0.9965 na 0.9935 0.3 
Azythromycin 0.9968 0.9924 na na na 0.9946 0.3 
Methiocarb 0.9952 0.9973 0.9726 0.9982 0.9974 0.9921 1.1 
Acetamiprid 0.9949 0.9946 0.9989 0.9927 0.9804 0.9932 0.7 
Clothianidin 0.9965 0.9939 0.9996 0.9996 0.9901 0.9959 0.4 
Imidacloprid 0.9927 0.9846 0.9890 0.9927 0.9932 0.9904 0.4 
Thiacloprid 0.9984 0.9957 0.9964 0.9894 0.9894 0.9938 0.4 
Thiamethoxam 0.9978 0.9984 0.9994 0.9888 0.9931 0.9955 0.4 
Oxadiazon 0.9838 0.9937 0.9927 0.9957 0.9976 0.9927 0.5 
Triallate 0.9999 0.9969 0.9984 0.9970 0.9984 0.9981 0.1 
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The study of the distribution of residuals revealed shapes heterogeneously distributed 
around the horizontal axis, proving the pertinence of the linear regression model for 
interpreting the data. The residual plots are shown in the following figures. 
Figure 19: EE2 residual plot  
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Figure 20: E2 residual plot 
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Figure 21: E1 residual plot 
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Figure 22: Diclofenac residual plot 
 
 
 Page 35 of 78 
 
Figure 23: BHT residual plot 
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Figure 24: EHMC residual plot 
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Figure 25: Azithromycin residual plot  
  
Figure 26: Clarithromycin residual plot  
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Figure 27: Methiocarb residual plot 
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Figure 28: Acetamiprid residual plot 
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Figure 29: Clothianidin residual plot 
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Figure 30: Imidacloprid residual plot 
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Figure 31: Thiacloprid residual plot 
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Figure 32: Thiamethoxam residual plot 
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Figure 33: Oxadiazon residual plot 
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Figure 34: Triallate residual plot 
  
 
3.3.1 Working range 
The working range, defined as the range of concentrations for which the chosen calibration 
curve is valid, was determined by the lowest and the highest calibration points in the 
respective calibration curve and matrix. Table 8 summarises the working ranges 
established in the procedure for the selected analytes both in MilliQ and surface water. 
Table 8: Working ranges of the analytical method 
Analyte Working range (ng/l) in 
MilliQ water 
Working range (ng/l) in 
surface water 
EE2 0.035-0.56 0.07-0.56 
E2  0.2-3.2 0.2-3.2 
Estrone  0.2-3.2 0.2-3.2 
Diclofenac 5-80 5-80 
BHT  375-6000 375-6000 
EHMC 780-12480 780-12480 
Clarythromycin 11.25-180 11.25-180 
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Azythromycin 11.25-180 11.25-180 
Methiocarb 1.25-20 1.25-20 
Acetamiprid 1.13-18.08 1.13-18.08 
Clothianidin 1.13-18.08 1.13-18.08 
Imidacloprid  1.13-18.08 1.13-18.08 
Thiacloprid 1.13-18.08 1.13-18.08 
Thiamethoxam 1.13-18.08 1.13-18.08 
Oxadiazon 11-176 11-176 
Triallate  83.75-1340 83.75-1340 
In case of EE2 determination in surface water, the lowest point of the calibration curve 
changed to 0.07 ng/l. 
In case of analytical determinations of concentration values included between the lowest 
point of the calibration curve and the estimated LOQ, an accurate verification of the validity 
of the linear model for data interpolation is recommended.  
It can be easily accomplished by analysing samples spiked at the opportune level.  
3.4 Matrix comparison 
The assumption verification and the ANCOVA analysis were carried out using the R 
software (5); the R code used for the analysis and the full computations are given in the 
Annex 1. A summary of the results is reported here. 
 
3.4.1 Verification of ANCOVA assumption 
3.4.1.1 Independence 
This assumption tests the independence of the covariate variable (concentrations of the 
standard) among groups (days). The full R outputs are given in Table 31 (MilliQ water), 
Table 32 (surface water) and Table 33 (matrix comparison) of the Annex 1.  
Table 9, provides summary results of the independence test. 
Since concentration levels of the covariate are equal for all days the computed p-value, 
resulting from the independence test, is 1 for all cases. With p-values greater than 0.05 
(95% level of confidence), the hypothesis of independence is accepted for all the 
compounds in the three specified cases. 
Table 9: Summary results of the independence test 
Compounds MilliQ water Lake water Matrix comparison 
17-α-Ethinyl estradiol True True True 
17-β-Estradiol True True True 
Estrone True True True 
Diclofenac True True True 
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Compounds MilliQ water Lake water Matrix comparison 
BHT True True True 
EHMC True True True 
Clarythromycin True True True 
Azythromycin True True True 
Methiocarb True True True 
Acetamiprid True True True 
Clothianidin True True True 
Imidacloprid True True True 
Thiacloprid True True True 
Thiamethoxam True True True 
Oxadiazon True True True 
Triallate True True True 
 
3.4.1.2 Normality 
To inspect if the distribution of residuals is normal, the quantile-quantile (Q-Q) plot is 
used. This graph plots the cumulative values of the data against the cumulative probability 
of a normal distribution. Each value is compared to the expected value that the score 
should have in a normal distribution and they are plotted against one another. 
If the residuals follow the normal distribution, then the points on the Q-Q plot will fall 
approximately on a straight line; deviations from the line show deviations from normality. 
Only significant departures from the line suggest violations of normality.  
When the sample size is small, as in the case under analysis, non-normality can be hard 
to detect. 
QQ-plots are given in Table 34 (MilliQ water), Table 35 (surface water) and Table 36 
(matrix comparison) of Annex 1. No significant deviation from normality is verified for all 
the analysed compounds in all three examined cases. 
3.4.1.3 Homogeneity of variance 
Levene’s test was used to determine if the variance in the outcome variable changes across 
groups. The full R output is given in Table 37 (MilliQ water), Table 38 (surface water) and 
Table 39 (matrix comparison) of Annex 1. Table 10 gives summary results of the 
homogeneity of variance test. 
For all the selected compounds in all the examined cases, Levene’s test results were non-
significant, with p-values always higher than 0.05 (95% confidence level). This means that 
the variances are very similar and the hypothesis of homogeneity of variances is accepted. 
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Table 10: Summary results of the homogeneity of variance test 
Compounds MilliQ water Surface water Matrix comparison 
17-α-Ethinyl estradiol True True True 
17-β-Estradiol True True True 
Estrone True True True 
Diclofenac True True True 
BHT True True True 
EHMC True True True 
Clarythromycin True True True 
Azythromycin True True True 
Methiocarb True True True 
Acetamiprid True True True 
Clothianidin True True True 
Imidacloprid True True True 
Thiacloprid True True True 
Thiamethoxam True True True 
Oxadiazon True True True 
Triallate True True True 
 
3.4.1.4 Linearity 
The assumption of linearity is checked by a simple inspection of the calibration scatterplots 
for each day separately. No outliers should occur. 
Calibration graphs reported in 3.2 provide a positive response for the linearity assumption. 
3.4.1.5 Homogeneity of regression slopes 
This assumption is verified by examining the scatter plot for each experimental condition 
(factor) with the covariate on one axis and the outcome on the other. The regression line 
for each of these scatter plots is then calculated, and the homogeneity of regression slopes 
is accepted if slopes are similar across factors. 
Calibration graphs reported in 3.3 show that slopes of the regression lines computed in 
different days are similar. 
 
3.4.2 Results of the ANCOVA analysis 
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ANCOVA was applied in order to compare slopes and intercepts of regression curves in the 
following three cases: 
a. five-day calibration curves for compounds analysed in MilliQ water; 
b. three-day calibration curves for compounds measured in surface water; 
c. two calibration curves, one in MilliQ water and one in surface water, for each 
compound, taken from the first two cases after accepting the equality of regression 
curves over days. 
All statistical analyses were performed using R software (5). The R code used for the 
ANCOVA analysis and the full R outputs are given in the Annex 1. 
3.4.2.1 Case a: MilliQ water 
The ANCOVA model was performed specifying five different slopes and five different 
intercepts (one a day). For the compounds Azythromycin and Clarythromycin, only two 
days were inspected. 
Based on the output of the ANCOVA computation, the hypothesis of equal slopes and the 
hypothesis of equal intercepts of regression lines were both accepted with p-values greater 
than 0.05 (95% confidence level). Full R output is given in Table 40 of Annex 1. 
Results confirm that the day on which the calibration curve was computed did not influence 
the output variable (concentration of the analyte) for all the selected compounds. 
3.4.2.2  Surface water 
The ANCOVA model was performed with three different slopes and three different 
intercepts (one a day). Full R output is given in Table 41 of Annex 1. 
From the ANCOVA results, choosing a confidence level of 95%, the hypothesis of equal 
slopes and intercepts between the regression lines was accepted (p-value>>0.05). 
Again, this indicates that the day on which the calibration curve was computed did not 
influence the output variable (concentration of the analyte) for all the selected compounds. 
3.4.2.3 MilliQ water v surface water 
After having tested the comparability of the calibration curved over days in the MilliQ water 
and surface water separately, it is possible to compare the calibration curves between the 
two water types. In this case, the ANCOVA will give us information about the effect of the 
matrix type. 
To compare the curves for the two waters, the first day calibration curve for each matrix 
type was used for the ANCOVA computation. The model was thus computed with two 
slopes and two intercepts. Full R output is given in Table 42 of Annex 1. 
Results show that the hypothesis of equal slope and equal intercept between the 
regression lines were both accepted with a 95% confidence level (p-value>>0.05). 
The two calibration curves deriving from the analysis in MilliQ water and surface water 
respectively and for all the selected compounds can, in conclusion, be assumed to be 
coincident at a level of confidence of 95%. This implies that the matrix type has no 
significant effect on calibration curves for the considered analyte. 
 
3.4.3 Conclusion of ANCOVA analysis 
From the ANCOVA analysis, for all the selected compounds, the calibration curves 
determined in MilliQ and in surface waters are coincident (same slopes and same 
intercepts).  
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For method validation purposes, the equivalence of the calibration curves in the two 
different matrices means that no new method validation needs to be carried out when the 
matrix type changes.  
Nevertheless, although results show slopes and intercepts of calibration curves to be 
coincident, LOD and LOQ values can be affected when changing from MilliQ to surface 
water matrix.  
As a consequence, proper checks of sensitivity performance of the entire analytical 
procedure is always recommended.  
3.5 Repeatability and intermediate precision 
For repeatability and intermediate precision, three QCs at two concentration levels were 
tested on three different days. Using one-way ANOVA, the results obtained are shown in 
Table 11. 
Table 11: RSDs of repeatability and intermediate precision 
Analyte 
Spiking 
level (ng/l) 
RSD of 
repeatability 
measurements 
RSD of intermediate 
precision measurements 
EE2 
0.0525 11.6 4.7 
0.42 4.8 9.7 
E2 
0.3 6.7 2.8 
2.4 2.9 2.8 
E1  
0.3 11.1 10.2 
2.4 6.1 5 
Diclofenac 
7.5 8.6 8.7 
60 9.8 6.2 
BHT 
450 8.2 11.8 
4500 4.4 5.1 
EHMC 
936 5.6 16.5 
9360 3.1 13.2 
Clarythromycin 
16.9 8 1.9 
135 5.5 4 
Azythromycin 
16.9 22 10 
135 8.3 10.1 
Methiocarb 
1.88 4.7 6.4 
15 3.2 7.2 
Acetamiprid 
1.7 6.2 10.3 
13.6 4.6 11 
Clothianidin 
1.7 10.2 7.4 
13.6 8 7.4 
Imidacloprid  
1.7 9.3 5.1 
13.6 9.7 4 
Thiacloprid 
1.7 6.7 9.3 
13.6 3.9 10.8 
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Thiamethoxam 
1.7 8.9 2.2 
13.6 7.4 8.2 
Oxadiazon 
16.5 2 5.8 
132 5.4 2.7 
Triallate 
101 9.9 5.8 
1005 12.1 4 
 
3.6 Extraction variability of trueness 
The extraction variability of trueness has been evaluated using the data from the standard 
addition experiments (i.e. three QCs at low and high concentration levels, extracted and 
analysed on three different days, for a total of nine independent replicates).  
Using the LINEST function provided by Excel, regression lines, obtained using the ‘least-
square method’, were calculated, interpolating QCs back-calculated concentrations and 
the corresponding theoretical values.  
The extraction variability was determined as slope % and is listed in Table 12. 
Table 12: Results of the extraction variability 
Analyte Slope  Extraction variability  
EE2  1.016 101.6 
E2  0.9807 98.07 
E1 1.059 105.9 
Diclofenac 0.9832 98.32 
BHT  1.0501 105.01 
EHMC 1.0592 105.92 
Clarythromycin 1.0352 103.52 
Azythromycin 1.0583 105.83 
Methiocarb 0.8381 83.81 
Acetamiprid 1.1069 110.69 
Clothianidin 1.0161 101.61 
Imidacloprid  1.0397 103.97 
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Analyte Slope  Extraction variability  
Thiacloprid 1.088 108.8 
Thiamethoxam 1.0381 103.81 
Oxadiazon 0.9282 92.82 
Triallate 0.8863 88.63 
 
3.7 Recovery 
The results of the recovery experiments, carried out using analyte-spiked MilliQ water and 
according to section 2.7, are listed in Table 13. 
Table 13: Recovery 
Analyte 
Spiking level 
(ng/l) 
Mean recovery 
(%) 
RSD (%) 
EE2 
0.035 112.4 8.8 
10 112.6 12.5 
E2  
0.035 100.2 1.6 
10 101.3 5.1 
E1 
0.035 98.2 4.6 
10 115.7 3.6 
Diclofenac 11.6 96.5 25.8 
BHT  
450 97.4 14.5 
4500 98.4 10.1 
EHMC 
936 69 6 
9360 101.8 14.1 
Azythromycin 10.4 81.4 24 
Clarythromycin 10.2 80.9 49 
Methiocarb 11 97.4 10.5 
Acetamiprid 13.8 101.4 8.0 
Clothianidin 12.8 89.3 10 
Imidacloprid  10 90.7 8.4 
Thiacloprid 10.8 95.1 7.7 
Thiamethoxam 9.8 92.0 11.4 
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Analyte 
Spiking level 
(ng/l) 
Mean recovery 
(%) 
RSD (%) 
Oxadiazon 12.2 99.2 24.4 
Triallate  
100.8 73.6 11.4 
1005 76.1 3.8 
Recovery of oestrogens has been tested at 0.035 and 10 ng/l levels.  
Concerning EE2, the evaluation of recovery at LOD level (i.e. 0.035 ng/l) had the aim of 
confirming the applicability of the procedure developed, considering the challenging level 
of sensitivity to be reached. 
Considering E2 and E1, spiking level of 0.035ng/l is one order of magnitude below the 
established maximum acceptable method detection limit (i.e. 0.4ng/l). Even considering 
the reduced reliability of these results, being below the studied working ranges, they 
clearly indicate the possibility of further decreasing the limits of detections for the selected 
oestrogens. 
Recovery of azithromycin and clarithromycin was tested at 10ng/l. This value is only 
slightly below the working range studied (i.e. 11.25-180ng/l), not significantly affecting 
the reliability of the results obtained. 
Recovery of BHT, EHMC and Triallate have been evaluated at low and high levels of QCs. 
 
3.8 Uncertainty estimation 
The estimation of measurement uncertainty was carried out following a top-down 
approach based on in-house validation data. The data derived from the validation of the 
method includes the sample preparation, standard dilution, and chromatographic and 
mass spectrometric detection variability. This approach takes into account the RSD of 
repeatability, the intermediate precision and the trueness measurements. The uncertainty 
of prepared standard stock solution is also considered.  
The expanded uncertainty was calculated using the following formula: 
       222Re2 StdippTness uuuukU   where: 
 
U is the expanded relative uncertainty, 
k is the coverage factor (k=2), 
uTness is the relative standard uncertainty of trueness estimation,  
uRep is the relative standard uncertainty of repeatability, 
uip is the relative standard uncertainty of intermediate precision, and 
uStd is the relative standard uncertainty related to calibration standards including weighing, 
purity and dilution contributions. 
3.8.1 Uncertainty of trueness 
uTness is the standard relative uncertainty associated with trueness.  
It is equal to the uncertainty of the extraction variability and calculated from the ratio 
between the relative uncertainty of slope and the slope, provided by LINEST function 
applied to standard addition experiment data.  
Uncertainty of Trueness = Uncertainty of the extraction variability (%)  
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3.8.2 Uncertainty of repeatability and intermediate precision  
uRep  and  uIp  are the standard relative uncertainties related to repeatability and 
intermediate precision measurements respectively. Individual contributions are calculated 
according to the following equations: 
uRep=√
(RSDRep)2
n Rep 
 and 
 
 
days
Ip
ip
n
RSD
u
2
    
where: 
RSDRep standard deviation of repeatability measurements, 
RSDIp standard deviation of intermediate precision measurements, 
nRep number of total replicates for repeatability measurements, and 
ndays number of days for intermediate precision measurements. 
 
3.8.3 Uncertainty of standard 
uStdu Std is the standard relative uncertainty associated with analytical standards used, and 
is calculated as follows: 
     222 balanceflaskanalyteStd uuuu   
ustd= √(uanalyte)
2 
 + (uflask)
2 
+ (ubalance)
2 
 
Uncertainty as reported in the certificates of analysis of used analytical standards are 
summarised in Table 14. 
Table 14: Uncertainty of analytical standard 
Analyte 
Uncertainty 
as stated in CoA 
EE2 
99.96±1.02µg/ml(k=2) 
1.02/99.96=0.0102 = U 
u=0.0102/2=0.005 
E2 
Purity 100% 
u=0 
E1 
99.0±1 µg/ml 
1/99.0=0.01=U, k=2 
u=0.01/2=0.005 
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Analyte 
Uncertainty 
as stated in CoA 
Diclofenac  
U=±0.5%=0.005, k=2 
u=0.005/2=0.0025 
BHT 
100±1 µg/ml 
1/100=0.01=U, k=2 
u=0.01/2=0.005 
EHMC 
Purity 98.9% 
u=1.1/100=0.011 
Azithromycin 
Titration 95.2% 
u=4.8/100=0.048 
Clarithomycin 
Purity 99.5% 
u=0.5/100=0.005 
Methiocarb 
Purity 99.5% 
u=0.5/100=0.005 
Acetamiprid 
Purity 99.9% 
u=0.1/100=0.001 
Clothianidin 
Purity 99.9% 
u=0.1/100=0.001 
Imidacloprid 
100.1±1.02 µg/kg (k=2) 
U=1.02/100.1=0.01 
u=0.01/2=0.005 
Thiacloprid 
Purity 99.9% 
u=0.1/100=0.001 
Thiamethoxam 
Purity 99.6% 
u=0.4/100=0.004 
Oxadiazon 
Purity 99.9% 
u=0.1/100=0.001 
Triallate 
Purity 98.8% 
u=1.2/100=0.012 
 
uFlask is the uncertainty related to the volumetric flask. The tolerance of the class A 10-ml 
volumetric flask (given by the manufacturer) is set to 0.04ml. As this value is not 
correlated with confidence level or distribution information, a rectangular distribution is 
assumed. 
For the uncertainty estimation, the relative tolerance value (i.e. 0.4%) must by divided by 
√3, giving a value of 0.231 for uFlask. 
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uSyringe is the uncertainty related to the withdrawal of the standard solution using a 1 000-
µl Hamilton syringe. As these syringes are manufactured to be accurate within ± 1% of 
the nominal value and this value is not correlated with confidence level or distribution 
information, a rectangular distribution is assumed. For the uncertainty estimation the 
relative uncertainty (i.e. 1ml/1000ml*100=0.1%) must by divided by √3, giving a value 
for uSyringe equal to 0.058. 
 
uBalance is the contribution from the weight of standards, and it is due to the linearity 
uncertainty of the balance from the calibration certificate. From balance linearity (± 
0.03 mg), a rectangular distribution is assumed to obtain a standard uncertainty; this 
contribution is considered twice, once for the tare and once for the gross weight. According 
to this approach, the uBalance as RSD % is: 
uBalance=
2
3
03.0
2 





x =0.035 
 
uBalance= %
10
035.0
mg
mg
= 0.35%. 
 
As the repeatability and trueness of the measurement were estimated for two different 
concentration levels, the uncertainty can also be estimated separately for low and high 
concentration levels. 
 
3.9 Final uncertainty budget  
Table 15 reports the detailed uncertainty budgets (contributions from trueness, 
repeatability, intermediate precision and standard purity) and results of uncertainty 
estimations at low and high concentration levels for each compound studied. 
The data are based on 95% confidence level (k=2), nine replicates (n1=9) on three 
different days (n2=3) for the evaluation of the uncertainty budget of validation and on 
single replicate (n1=1) in a single day (n2=1) for the uncertainty budget of method 
application. 
Table 15: Uncertainty budget and estimated uncertainty of measurements 
Analyte 
k, n1, 
n2 
Conc 
(ng/l) 
UTness 
(%) 
uRep 
(%) 
uIp 
(%) 
uStd 
Expanded relative 
uncertainty 
(%) (U, %) 
EE2 
2, 9, 3 
0.0525 3.7 3.9 2.7 0.3 12 
0.42 3.7 1.6 5.6 0.3 14 
2, 1, 1 
0.0525 3.7 11.6 4.7 0.3 26 
0.42 3.7 4.8 9.7 0.3 23 
E2 
2, 9, 3 
0.3 1.5 2.2 1.6 0.3 6 
2.4 1.5 1 1.6 0.3 5 
2, 1, 1 
0.3 1.5 6.7 2.9 0.3 15 
2.4 1.5 2.9 2.8 0.3 9 
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Analyte 
k, n1, 
n2 
Conc 
(ng/l) 
UTness 
(%) 
uRep 
(%) 
uIp 
(%) 
uStd 
Expanded relative 
uncertainty 
(%) (U, %) 
E1 
2, 9, 3 
0.3 3.5 3.7 5.9 0.3 16 
2.4 3.5 2 2.9 0.3 10 
2, 1, 1 
0.3 3.5 11.1 10.2 0.3 31 
2.4 3.5 6.1 5 0.3 17 
Diclofenac 
2, 9, 3 
7.5 4.3 2.9 5 0.4 14 
60 4.3 3.3 3.6 0.4 13 
2, 1, 1 
7.5 4.3 8.6 8.7 0.4 26 
60 4.3 9.8 6.2 0.4 25 
BHT 
2, 9, 3 
450 2.3 2.7 6.8 0.3 15 
4500 2.3 1.5 2.9 0.3 8 
2, 1, 1 
450 2.3 8.2 11.8 0.3 29 
4500 2.3 4.4 5.1 0.3 14 
EHMC 
2, 9, 3 
936 4.4 1.9 9.5 0.3 21 
9360 4.4 1 7.6 0.3 18 
2, 1, 1 
936 4.4 5.6 16.5 0.3 36 
9360 4.4 3.1 13.2 0.3 29 
Azithromycin 
2, 9, 3 
16.875 4.5 2.7 1.1 0.3 21 
135 4.5 1.8 2.3 0.3 16 
2, 1, 1 
16.875 4.5 8 1.9 0.4 49 
135 4.5 5.5 4 0.4 45 
Clarithromycin 
2, 9, 3 
16.875 2.5 7.4 5.8 0.3 8 
135 2.5 2.8 5.8 0.3 8 
2, 1, 1 
16.875 2.5 22.1 10 0.3 17 
135 2.5 19.4 10.1 0.3 15 
Methiocarb 
2, 9, 3 
1.875 2.6 1.6 3.7 0.3 10 
15 2.6 1.1 4.2 0.3 10 
2, 1, 1 
1.875 2.6 4.7 3.2 0.3 17 
15 2.6 6.4 7.2 0.3 17 
Acetamiprid 
2, 9, 3 
1.695 4 2.1 5.9 0.3 15 
13.56 4 1.5 6.4 0.3 15 
2, 1, 1 
1.695 4 6.2 10 0.3 25 
13.56 4 4.6 11 0.3 25 
Clothianidin 
2, 9, 3 
1.695 3.9 3.4 4.3 0 13 
13.56 3.9 2.7 4.3 0.3 13 
2, 1, 1 
1.695 3.9 10.2 7.4 0.3 26 
13.56 3.9 8 7.4 0.3 23 
Imidacloprid 2, 9, 3 1.695 4.8 3.1 2.9 0.3 13 
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Analyte 
k, n1, 
n2 
Conc 
(ng/l) 
UTness 
(%) 
uRep 
(%) 
uIp 
(%) 
uStd 
Expanded relative 
uncertainty 
(%) (U, %) 
13.56 4.8 3.2 2.3 0.3 12 
2, 1, 1 
1.695 4.8 9.3 5.1 0.3 23 
13.56 4.8 9.7 4 0.3 23 
Thiacloprid 
2, 9, 3 
1.695 3.8 2.2 5.4 0.3 14 
13.56 3.8 1.3 6.2 0.3 15 
2, 1, 1 
1.695 3.8 6.7 9.3 0.3 24 
13.56 3.8 3.9 10.8 0.3 24 
Thiamethoxam 
2, 9, 3 
1.695 3.9 3 1.3 0.3 10 
13.56 3.9 2.5 4.7 0.3 13 
2, 1, 1 
1.695 3.9 8.9 2.2 0.3 20 
13.56 3.9 7.4 8.2 0.3 23 
Oxadiazon 
2, 9, 3 
16.5 2.3 0.7 3.3 0.3 8 
132 2.3 1.8 1.6 0.3 7 
2, 1, 1 
16.5 2.3 2 5.8 0.3 13 
132 2.3 5.4 2.7 0.3 13 
Triallate 
2, 9, 3 
100.8 2.3 3.3 3.3 0.3 11 
1005 2.3 4 2.3 0.3 10 
2, 1, 1 
100.8 2.3 9.9 5.8 0.3 23 
1005 2.3 12.1 4 0.3 26 
 
4 Conclusions 
SPE-LC-MS/MS and LLE-GC-MS multi-compound methods developed and described in this 
report are fit for purpose for the quantitative determination of environmental contaminants 
selected in the first watch list for surface water monitoring. 
Appropriately cross-validated and applied, they will enable MS laboratories to collect 
environmental data in support of future prioritisation exercises in accordance with Article 
16(2) of the Directive 2000/60/EC of the European Parliament and of the Council.  
Based on EE2 results it is recommended that LOD and LOQ be evaluated individually on 
each real sample analysed, accounting for various types of matrix interferences.  
LOD value in real samples can be obtained from the S/N (usually a S/N of 3:1 is applied). 
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List of abbreviations and definitions  
Chemical elements are identified by their respective symbols as defined by the 
International Union of Pure and Applied Chemistry (IUPAC).  
Throughout this report, the following abbreviations and symbols are used: 
ANOVA Analysis of variance 
ANCOVA Analysis of Covariance 
BHT 2.6-Ditert-butyl-4-methylphenol 
CAD Collision Gas  
CUR Curtain Gas 
CRM Certified reference material 
CXP Collision Cell Exit Potential 
DG Directorate-General 
E1 Estrone 
E2 17-estradiol 
EE2 17-ethinyl estradiol 
EC European Commission 
EHMC 2-Ethylhexyl-methoxycinnamate 
EI Electron Impact 
EP Entrance Potential 
EU European Union 
GC  Gas chromatography 
GS1 Ion Source gas 1 
GS2 Ion Source gas 2 
HLB Hydrophilic-lipophilic balance 
IES Institute for Environment and 
Sustainability 
IS Internal standard/Ion Transfer 
voltage 
ISO International Organisation for 
Standardisation 
JRC Joint Research Centre 
LC Liquid chromatography 
LOD Limit of detection 
LOQ Limit of quantification 
MRM Multiple reaction monitoring 
MS Mass spectrometry 
PPG Polypropylene glycol 
PS Priority substances 
QC Quality control sample 
R2 Coefficient of determination 
RSD Relative standard deviation 
RT Room temperature / retention 
time 
SD Standard deviation 
S/N Signal to Noise  
SPE Solid-phase extraction 
TEM Temperature 
UHPLC Ultra-high-pressure liquid 
chromatography 
WFD Water Framework Directive 
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General recommendation 
It was observed that an operator’s use of an ordinary face cream containing EHMC heavily 
influenced the analysis results of said compound even though gloves were worn during all 
handling. It is therefore highly recommended that operators verify that any body creams 
used do not contain any EHMC. This problem has also been reported in earlier studies of 
the compound (Kameda et al., Environmental Pollution, 159, (2011), 1570-1576).  
For estrogen analysis, it is highly recommended that the aqueous sample be stored in the 
dark at 4 C and to perform extraction and analysis as soon as possible, within 48 hours 
from collection (Gabet, V. et al., Trends in Anal. Chem., 26, 11, 2007, 1113-1131). 
1 Chemicals  
1.1 Standards 
Native and labelled standards were commercially purchased and their technical data are 
summarised in Table 16 and Table 17.  
Table 16: Analytical standards 
Analytev 
(unlabelled) 
CAS  Batch  Purity Expiry date Supplier 
EE2 57-63-6 SDEE-021 ≥ 98 % 6/25/2024 CIL  
E2 50-28-2 PR-25021 ≥ 98 % 11/01/2018 CIL 
E1 100 g/ml in 
acetonitrile 
53-16-7 SDDF-016 ≥ 98 % 10/04/2023 CIL 
Diclofenac 
15307-79-
6 
30226 99.5 % 11/02/2017 Dr Ehrenstorfer 
BHT 100 g/ml in 
nonane  
128-37-0 SDDDE-023 ≥ 98 % 7/19/2023 CIL 
EHMC 5466-77-3 BCBK1010V 98.9 % 
See Product Dating 
Information 
Statement from 
Sigma 
Sigma-Aldrich 
Azythromycin 
83905-01-
5 
446421/1 V 95.2 % 
See Product Dating 
Information 
Statement from 
Sigma 
Sigma-Aldrich 
Clarythromycin 
81103-11-
9 
084M4134V 99.5 % 04/30/2016 Sigma-Aldrich 
Methiocarb 2032-65-7 SZDB302XV 99.5 % 10/29/2018 Sigma-Aldrich 
Acetamiprid 
135410-
20-7 
SZBC110XV 99.9 % 04/19/2017 Sigma-Aldrich 
Clothianidin 
210880-
92-5 
SZBD053XV 99.9 % 02/22/2017 Sigma-Aldrich 
Imidacloprid 100 g/ml 
in methanol  
13826-41-
3 
SCIK-006 ≥ 98 % 01/26/2019 CIL 
Thiacloprid 
111988-
49-9 
SZDB234XV 99.9 % 08/22/2017 Sigma-Aldrich 
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Analytev 
(unlabelled) 
CAS  Batch  Purity Expiry date Supplier 
Thiamethoxam 
153719-
23-4 
SZBC031XV 99.6 % 01/31/2017 Sigma-Aldrich 
Oxadiazon 
19666-30-
9 
SZBD324XV 99.9 % 11/20/2018 Sigma-Aldrich 
Triallate  2303-17-5 SZBX301XV 98.8 % 10/28/2018 Sigma-Aldrich 
 
Table 17: Labelled analytical standards 
Labelled analogues Batch  Purity Expiry date Supplier 
EE2 (2,4,16,16-d4) PR-24836 
97-
98 % 
Stable if stored at RT away from 
light and moisture 
CIL  
E2 (2,4,16,16-d4) PR-10457 
95-
97 % 
Two years after receipt if stored 
at RT away from light and 
moisture 
CIL 
E1 (2,3,4-13C3) 50 g/ml in 
methanol 
I-19311 ≥ 99 % 
Stable if stored frozen (-20° C) 
and protected from light  
CIL 
Diclofenac-(acetophenyl 
ring 13C6) 
SZBE136XV 99.6 % 
See Product Dating Information 
Statement from Sigma 
Sigma-Aldrich 
BHT (d21)  I-17754 98 % 
Stable if stored at RT away from 
light and moisture 
CIL 
Erythromycin (n,N-
dimethyl-13C2) 100 g/ml in 
MTBE 
SDEJ-012 ≥ 90 % 12/19/2024 CIL 
Acetamiprid-d3 1438678 V 99.7 % 
See Product Dating Information 
Statement from Sigma 
Sigma-Aldrich 
Clothianidin-d3 BCBN8335V 99.1 % 01/31/2018 Sigma-Aldrich 
Imidacloprid (4,4,5,5-d4) 
100 g/ml in methanol  
SCIK-005 ≥ 98 % 01/26/2019 CIL 
Thiacloprid d4 T242A150303 99.8 % 03/03/2018 
Analytical 
Standard 
Solutions  
Thiamethoxam d3 1438684 V 99.1 % 05/31/2016 Sigma-Aldrich 
p-Terphenyl-d14 PAHSSB1011 > 98 % 03/01/2017 Wellington Lab. 
 
1.2 Materials and reagents 
Methanol, code 701091.1612, (LC-MS) PAI, Panreac Química, Barcelona (Spain). 
Acetonitrile, code 701881.1612, (LC-MS) PAI, Panreac Química, Barcelona (Spain). 
Ammonium acetate 99.99+ %, metal basis, code 431311-50g, Aldrich. 
Ammonium hydroxide solution ≥ 25 %, code 44273-100 ml, Fluka. 
Hexane, code 34412-2.5L, for analysis of dioxins, furans and PCBs, Fluka. 
Acetone, code 1.00012.2500, SupraSolv, Merck.  
Toluene, code 1.08389.2500, SupraSolv, Merck.  
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MilliQ water obtained from a MilliQ water system, Millipore, Bedford, MA (USA). 
OASIS HLB cartridges 6CC (0.2g), code WAT106202, Waters, Milford, MA, USA. 
 
1.3 Reagent solutions for LC-MS/MS 
Mobile phase A1: CH3COONH4 10 mM pH 3: 0.077 g of CH3COONH4 was dissolved in 1 l 
MilliQ water and adjusted to pH 3 with CH3COOH. 
 
Mobile phase B1: Methanol: 1000 ml methanol was degassed using ultrasonic bath for 20 
seconds. 
 
Mobile phase A2: 0.1 % NH4OH: 1.96ml NH4OH 25 % was dissolved in 0.5 l water and 
degassed using ultrasonic bath for 20 seconds. 
 
Mobile phase B2: Acetonitrile: 1000 ml acetonitrile was degassed using ultrasonic bath for 
20 seconds. 
 
UHPLC Autosampler strong washing solution: 900 ml of water and 100 ml of methanol 
were mixed and degassed using ultrasonic bath for 20 seconds. 
 
UHPLC Autosampler weak washing solution: 100ml of water and 900 ml of methanol were 
mixed and degassed using ultrasonic bath for 20 seconds. 
 
UHPLC Seal washing solution: same as UHPLC Autosampler weak washing solution. 
 
UHPLC-MS/MS Reconstituting solution for LC-MS/MS analysis: 900ml water was mixed 
with 100 ml actonitrile. 
2 Standard solutions 
2.1 Standard solutions of native compounds 
Whenever available, analytical standards in solution were purchased. 
For chemical standards purchased as solid, stock standard solutions were prepared in 
methanol, as described below. 
 
Diclofenac stock standard solution (1160 µg/ml): 11.6 mg of diclofenac was dissolved with 
10 ml methanol in a 10-ml volumetric flask. 
 
EHMC stock standard solution (1040 µg/ml): 10.4 mg of EHMC was dissolved with 10 ml 
methanol in a 10-ml volumetric flask. 
 
EHMC working standard solution (10.4 µg/ml): 0.1 ml of EHMC stock standard solution 
was diluted with methanol in a 10-ml volumetric flask. 
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Clarithromycin stock standard solution (1020 µg/ml): 10.2 mg of Clarithromycin was 
dissolved with 10 ml methanol in a 10-ml volumetric flask. 
 
Azithromycin stock standard solution (1040 µg/ml): 10.4 mg of Azithromycin was 
dissolved with 10 ml methanol in a 10-ml volumetric flask. 
 
Methiocarb stock standard solution (1100 µg/ml): 11 mg of Methiocarb was dissolved with 
10 ml methanol in a 10-ml volumetric flask. 
 
Acetamiprid stock standard solution (1380 µg/ml): 13.8 mg of Acetamiprid was dissolved 
with 10 ml methanol in a 10-ml volumetric flask. 
 
Clothianidin stock standard solution (1 280 µg/ml): 12.8 mg of Clothianidin was dissolved 
with 10 ml methanol in a 10-ml volumetric flask. 
 
 
Thiacloprid stock standard solution (1080 µg/ml): 10.8 mg of Thaicloprid was dissolved 
with 10 ml methanol in a 10-ml volumetric flask. 
 
Thiametoxam stock standard solution (980 µg/ml): 9.8 mg of Thiamethoxam was 
dissolved with 10 ml methanol in a 10-ml volumetric flask. 
 
Working standard solution for spiking 1 l MilliQ water samples for linearity study was 
prepared according to the scheme reported below: 
 
Triallate stock standard solution (1340 µg/ml):13.4 mg of triallate was dissolved with 10 
ml methanol in a 10-ml volumetric flask. 
 
Triallate working standard solution (1.34 µg/ml): 0.01 ml of Triallate stock standard 
solution was diluted with 10 ml methanol in a 10-ml volumetric flask.  
 
Two different sets of working solution were prepared. The first included the analytes 
monitored by LC-MS/MS and the second included the compounds to be analysed by GC-
MS. 
 
Working standard solution for LC-MS/MS were prepared according to the scheme described 
below: 
 
Standard Solution E for LC-MS/MS 
The volumes of stock standard solution indicated in Table 18 were diluted with methanol 
into a total volume of 10 ml using a volumetric flask. 
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Table 18: Preparation of working standard solution E for LC-MS 
Analyte for LC-
MS analysis 
Stock sol. 
Conc (µg/ml) 
Withdrawn 
volume (ml) 
Standard solution 
E Conc. (ng/ml) 
EE2 100 0.0056 56 
E2 100 0.0320 320 
E1 100 0.0320 320 
Diclofenac 1160 0.0690 8000 
Clarythromycin 1020 0.1765 18000 
Azythromycin 1040 0.1731 18000 
Methiocarb 1100 0.0182 2000 
Acetamiprid 1380 0.0131 1808 
Clothianidin 1280 0.0141 1 808 
Imidacloprid 100 0.1808 1808 
Thiacloprid 1080 0.0167 1808 
Thiamethoxam 980 0.0184 1808 
Oxadiazon 1220 0.1443 17600 
 
Working standard solution for GC-MS were prepared according to the scheme described 
below: 
 
Standard Solution E for GC-MS 
The volumes of stock standard solution indicated in Table 19 were diluted with methanol 
into a total volume of 10 ml using a volumetric flask. 
Table 19: Preparation of working standard solution E for GC-MS 
Analyte for GC-
MS analysis 
Stock sol. Conc 
(µg/ml) 
Withdrawn 
volume (ml) 
Standard solution 
E Conc. (ng/ml) 
BHT 100 0.06 600 
EHMC 10.4 1.2 1248 
Triallate 1.34 1 134 
 
 
Standard Solution D, C, B and A 
Consecutive serial dilutions 1:1 from standard solutions E, both for LC-MS/MS and for GC-
MS, originated standard solutions D, C, B and A according to Table 20 for LC-MS/MS and 
Table 21 for GC-MS. 
Table 20: Preparation of diluted working standard solutions for LC-MS/MS 
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Analyte 
Standard Sol. 
D (ng/ml) 
Standard Sol. 
C (ng/ml) 
Standard Sol. 
B (ng/ml) 
Standard Sol. 
A (ng/ml) 
EE2 28 14 7 3.5 
E2 160 80 40 20 
E1 160 80 40 20 
Diclofenac 4000 2000 1000 500 
BHT 300 150 75 37.5 
EHMC 624 312 156 78 
Clarythromycin 9000 4500 2250 1125 
Azythromycin 9000 4500 2250 1125 
Methiocarb 1000 500 250 125 
Acetamiprid 904 452 226 113 
Clothianidin 904 452 226 113 
Imidacloprid 904 452 226 113 
Thiacloprid 904 452 226 113 
Thiamethoxam 904 452 226 113 
Oxadiazon 8800 4400 2200 1 00 
Triallate 67 33.5 16.75 8.375 
 
Table 21: Preparation of diluted working standard solutions for GC-MS 
Analyte 
Standard Sol. 
D (ng/ml) 
Standard Sol. 
C (ng/ml) 
Standard Sol. 
B (ng/ml) 
Standard Sol. 
A (ng/ml) 
BHT 300 150 75 37.5 
EHMC 624 312 156 78 
Triallate 67 33.5 16.75 8.375 
 
2.2 Standard solutions of labelled analogues 
Whenever available, stock standard solutions of labelled analogues were purchased. 
For labelled standards purchased as solid, stock standard solutions were prepared in 
methanol, as described below: 
 
2.2.1 Labelled analogues mixture for LC-MS/MS determination 
 
EE2 d4 stock standard solution (0.1mg/ml): 1 mg 17-ethynyl estradiol d4 was dissolved 
with methanol in a 10-ml flask. 
 
E2 d4 stock standard solution 1(5 mg/ml): 5 mg of 17-estradiol d4 was dissolved in 
methanol in a 10-ml volumetric flask. 
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E2 d4 stock standard solution 2 (0.1 mg/ml): 0.02 ml of 17-estradiol d4 5 mg/ml was 
diluted with methanol into total volume of 10-ml using a volumetric flask. 
 
Diclofenac 13C6 stock standard solution (0.11 mg/ml): 1.1 mg of diclofenac 13C6 was 
dissolved with methanol in a 10-ml volumetric flask. 
 
Acetamiprid d3 stock standard solution (0.11 mg/ml): 0.1 mg of acetamiprid d3 was 
dissolved with methanol in a 10-ml volumetric flask. 
 
Clothianidin d3 stock standard solution (0.12 mg/ml): 1.2 mg of clothianidin d3 was 
dissolved with methanol in a 10-ml volumetric flask. 
 
Thiacloprid d4 stock standard solution (0.11 mg/ml): 1.1 mg of thiacloprid d4 was dissolved 
with methanol in a 10-ml volumetric flask. 
 
Thiamethoxam d3 stock standard solution (0.13 mg/ml): 1.3 mg of thiamethoxam d3 was 
dissolved with methanol in a 10-ml volumetric flask. 
  
 Page 71 of 78 
 
Interna Standard Working Solution for LC-MS/MS  
The volumes of individual stock standard solution indicated in 7 were diluted with methanol 
into total volume of 10 ml using a volumetric flask. 
 
Table 22: Preparation of internal standard working solution for LC-MS/MS 
Compound 
Withdraw 
(ml) 
Final 
Volume(mL) 
MeOH 
Working Internal 
Standard Sol. 
Conc (ng/ml) 
EE2-d4 0.01 10 100 
E2-d4 0.01 10 100 
E1 13C3 0.02 10 100 
Diclofenac 13C6 0.01 10 110 
Erythromycin 13C2 0.01 10 100 
Acetamiprid-d3 0.01 10 110 
Clothianidin-d3 0.01 10 120 
Imidacloprid-d4 0.01 10 100 
Thiacloprid-d4 0.01 10 110 
Thiamethoxam-d3 0.01 10 130 
 
2.2.2 Labelled analogues solutions for GC-MS determination 
Whenever available, stock standard solutions of labelled analogues were purchased. 
For BHT d21, stock standard solution was prepared in methanol, as described below: 
 
BHT d21 stock standard solution (0.18 mg/ml): 1.8 mg of BHT d21 was dissolved with 
methanol in a 10-ml volumetric flask. 
 
Internal Standard working solutions for GC-MS determination was prepared according to 
the dilution scheme reported inTable 23. 
Table 23: Preparation of internal standard working solution for GC-MS 
Compound Withdraw (ml) 
Final volume (mL) 
acetone 
Working Internal 
Standard Sol. Conc 
(ng/ml) 
BHT-d21 0.02 20 180 
p-Terphenyl-d14 0.4 10 200 
 
3 Apparatus 
Analytical balance:  Model AX204, Mettler-Toledo SpA. 
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Automatic pipettes:  Eppendorf research (Milan, Italy). 
Microsyringes:  Microliter Syringes, Hamilton (Reno, CA, USA). 
Autosampler vials for LC-MS: Micro-V vials target Dp clear, 1.5 ml, 12x22 mm 
National Scientific (Germany). 
Volumetric flasks:  Grade A various sizes, Duran®. 
Volumetric pipettes:  Grade A various sizes, Duran®. 
Dionex Autotrace AT280 automated SPE system (Thermo Scientific, Waltham, MA, USA). 
TurboVap II (Caliper Life Science, Mountain View, CA, USA). 
Vortex Genius, Ika, Staufen, Germany. 
Horizontal shaker, GFL 3018. 
4 Instrumental equipment and conditions 
4.1 LC-MS/MS equipment and conditions  
Pumps: Binary Solvent Manager, Model UPB, Waters (Milford, MA, USA). 
Autosampler: Sample Manager, Model UPA, Waters (Milford, MA, USA). 
Detector: QTRAP 5500, Applied Biosystems MDS SCIEX, (Foster City, CA, USA) 
equipped with Turbo V™ ion source. 
Flow rate: 400 µl/min. 
Injection volume: 5 µl in ESI_WL2015_All_SCHED.dam method and 30 µl in 
ESI_WL2015_EstrogenSCHED.dam method. 
Analytical column: Hypersil GOLD, 1.9 µm, 50 x 2.1 mm, Thermo Scientific (for both 
methods). 
 
Two different UHPLC-MS/MS methods were developed and optimised for the quantification 
of selected chemicals. Methods are named as follows: 
 
 ESI_WL2015_EstrogenSCHED.dam, and  
 
 ESI_WL2015_All_SCHED.dam. 
 
The method ESI_WL2015_All_SCHED.dam was used for the quantification of diclofenac, 
azithromycin, clarithromycin, methiocarb, acetamiprid, clothianidin, imidacloprid, 
thiacloprid, thiametoxamm, oxadiazon. By polarity switching, using Analyst 1.6 scheduling 
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algorithm, this accomplished the quantification of the selected compounds in positive 
polarity with the exception of diclofenac which was quantified in negative polarity. 
Chromatography was performed in gradient mode according to the scheme described in 
Table 24. 
Table 24: Gradient scheme for ESI_WL2015_All_SCHED.dam method 
Time  A: CH3COONH4, 10 mM ph 3 B: MeOH Flow (ml/min) 
0 90 10 0.4 
0.1 90 10 0.4 
5 10 90 0.4 
5.1 90 10 0.4 
8 90 10 0.4 
Under these conditions, the selected analytes eluted at the retention time are listed in 
Table 25. 
Table 25 Retention time in ESI_WL2015_All_SCHED.dam method 
Analyte RT (minutes) 
Diclofenac 5.4 
Azythromycin 4.8 
Clarythromycin 4.8 
Methiocarb 4.9 
Acetamiprid 3 
Clothianidin 2.7 
Imidacloprid 2.7 
Thiacloprid 3.3 
Thiamethoxam 2.3 
Methiocarb 4.9 
Oxadiazon 6 
  
The run time was about 8 minutes. 
The method ESI_WL2015_EstrogenSCHED.dam was used for the quantification of EE2, E2 
and E1 in negative polarity. 
Chromatography was performed in gradient mode according to the scheme described in 
Table 26. 
Table 26: Gradient scheme for ESI_WL2015_EstrogenSCHED.dam method 
Time (minutes)  A: 0.1% NH4OH  B: AcN Flow (ml/min) 
0 90 10 0.4 
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0.5 90 20 0.4 
1 60 40 0.4 
5 10 90 0.4 
6 10 90 0.4 
6.5 90 10 0.4 
12 90 10 0.4 
Under these conditions, monitored analytes eluted at the following retention times: EE2 
at 3.2 min, E2 at 3.1 min, E1 at 3.3 min. The run time was 12 minutes. 
An AB Sciex QTRAP5500 mass spectrometer equipped with Turbo V™ ion source was used. 
The instrument was previously tuned and calibrated in electrospray mode using 
polypropylene glycol (PPG). Prior to analysis, all the specific parameters were optimised 
infusing a 1 µg/ml standard solution of analyte and IS.  
The eluent from the column was introduced directly into the ion source. The rapid 
desolvation and vaporisation of the droplets minimises thermal decomposition and 
preserves their molecular identity. The data were collected using the software programme 
Analyst 1.6. 
All calculations were based on chromatographic peak area ratios for the multiple reaction 
monitoring (MRM) precursor-product ion transitions for analyte to the precursor-product 
ion transition of the IS. Analyst 1.6 software was used for data acquisition and data 
processing.  
Statistical calculations were performed using Excel software. 
 
The general operating conditions were as follows: 
Scan Type:  Scheduled MRM 
Polarity:  Positive/Negative  
Ion Source:  Turbo Spray 
Resolution Q1:  Unit 
Resolution Q3:  Unit 
MR Pause:  5.0000 msec 
 
Table 27 summarises MRM selected transitions, retention time, operative instrumental 
parameters and internal standard of ESI_WL2015_All_SCHED.dam method. 
Table 27: LC-MS/MS parameters ESI_WL2015_All_SCHED.dam method 
ESI_WL2015_All_SCHED.dam 
Analyte MRM  
Q1 Q3 RT (min) Analyte ID DP (V) EP (V) CE (V) CXP (V) 
Internal 
Standard 
294 250 5.4 Diclofenac -42 -10 -16 -11 
 294 214 5.4 Diclofenac 1 -42 -10 -29 -11 
300 256 5.4 Diclofenac 13C6 -173 -10 -15 -11 
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ESI_WL2015_All_SCHED.dam 
Analyte MRM  
Q1 Q3 RT (min) Analyte ID DP (V) EP (V) CE (V) CXP (V) 
Internal 
Standard 
300 220 5.4 Diclofenac 13C6 1 -173 -10 -29 -11 
749.6 591.4 4.8 Azythromycin 200 10 40 13 
Erythromycin 
13C2 749.6 573.3 4.8 Azythromycin 1 200 10 47 13 
748.5 590.5 4.8 Clarythromycin 100 10 28 13 
Erythromycin 
13C2 748.5 558.5 4.8 Clarythromycin 1 100 10 31 13 
736 578 4.4 Erythromycin 13C2 130 10 26 13  
736 560 4.4 Erythromycin 13C2 1 130 10 26 13  
736 130 4.4 Erythromycin 13C2 2 160 10 36 13  
226 169 4.9 Methiocarb 30 10 12 13 
Thiacloprid-d4 
226 121 4.9 Methiocarb 1 30 10 25 13 
223 126 3 Acetamiprid 80 10 29 13 
Acetamiprid-d3 
223 73 3 Acetamiprid 1 80 10 76 13 
225 128 3 Acetamiprid 2 80 10 29 13 
225 75 3 Acetamiprid 3 80 10 74 13 
226 126 3 Acetamiprid-d3 80 10 27 13  
226 73 3 Acetamiprid-d3 1 80 10 80 13  
226 190 3 Acetamiprid-d3 2 80 10 19 13  
250 132 2.7 Clothianidin 50 10 26 13 
Clothianidin-d3 250 169 2.7 Clothianidin 1 50 10 16 13 
252 134 2.7 Clothianidin 2 50 10 24 13 
253 172 2.7 Clothianidin-d3 1 50 10 18 13  
253 132 2.7 Clothianidin-d3 1 50 10 23 13  
256 209 2.7 Imidacloprid 60 10 21 13 
Imidacloprid-d4 
256 175 2.7 Imidacloprid 1 60 10 27 13 
260 213 2.7 Imidacloprid-d4 60 10 26 13  
260 179 2.7 Imidacloprid- d4 1 60 10 29 13  
253 126 3.3 Thiacloprid 100 10 27 13 
Thiacloprid-d4 
253 90 3.3 Thiacloprid 1 100 10 55 13 
255 128 3.3 Thiacloprid 2 77 10 28 13 
255 90 3.3 Thiacloprid 3 77 10 53 13 
257 126 3.3 Thiacloprid-d4 100 10 28 13  
257 73 3.3 Thiacloprid-d4 1 100 10 83 13  
257 90 3.3 Thiacloprid-d4 2 100 10 54 13  
292 132 2.3 Thiamethoxam 60 10 35 13 
Thiamethoxam-
d3 292 211 2.3 Thiamethoxam 1 60 10 18 13 
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ESI_WL2015_All_SCHED.dam 
Analyte MRM  
Q1 Q3 RT (min) Analyte ID DP (V) EP (V) CE (V) CXP (V) 
Internal 
Standard 
295 214 2.3 Thiamethoxam-d3 70 10 19 13  
295 132 2.3 Thiamethoxam-d3 1 70 10 30 13  
345 220 6 Oxadiazon 90 10 28 13 
Thiacloprid-d4 
345 303 6 Oxadiazon 1 90 10 21 13 
 
Table 28: LC-MS/MS parameters ESI_WL2015_EstrogenSCHED.dam 
ESI negative (ESI_WL2015_EstrogenSCHED.dam) 
Analyte MRM  
Q1 Q3 RT (min) Analyte ID DP (V) EP (V) CE (V) CXP (V) 
Internal 
standard 
295 67 2 EE2 -100 -10 -70 -11 EE2 d4 
295 145 3.2 EE2 -100 -10 -70 -11  
295 143 3.2 EE2 1 -100 -10 -50 -11  
299 145 3.2 EE2 d4 -100 -10 -60 -11  
299 187 3.2 EE2 d4 1 -100 -10 -45 -11  
271 145 3.1 E2 -83 -10 -60 -11 E2 d4 
271 143 3.1 E2 1 -83 -10 -78 -11  
275 147 3.1 E2 d4 -100 -10 -55 -11  
275 187 3.1 E2 d4 1 -100 -10 -50 -11  
269 145 3.3 E1 -100 -10 -53 -11 E1 13C3 
269 143 3.3 E1 1 -100 -10 -74 -11  
272 146 3.3 E1 13C3 -150 -10 -88 -11  
272 148 3.3 E1 13C3 1 -150 -10 -50 -11  
 
Further operative instrumental parameters were optimised as follows: 
 
Curtain gas (CUR)     25 
Collision gas (CAD)     Medium 
Temperature (TEM)     550 
Ion Transfer Voltage (IS)    -4500 
Entrance Potential (EP)   10.00 
Collision cell Exit Potential (CXP)  -11.00 
Ion Source gas 1 (GS1)   55 
Ion Source gas 2 (GS2)   45 
 Page 77 of 78 
 
 
4.2 GC-MS equipment and conditions 
Autosampler:  CTC Analytics GC PAL  
Gas chromatograph:  Thermofisher Trace 1 310 
Analytical column:  Agilent HP-5 MS UI, length 
30 m, diameter 0.25 mm, 
film: 0.25 µm  
Mass spectrometer:  Thermofisher Ion Trap ITQ 
1 100 
Table 29: GC-MS parameters 
GC-MS PARAMETERS 
Temperature programme 100°C for 1 min.; 10°C/min to 
300°C; 300°C for 5 min. 
Column flow (ml/min) 1 
Splitless (min) 1 
Injection volume (µl) 2  
Ionisation EI at 70 eV 
Scan mode Full Scan 50-500 amu 
Max Ion Time (msec) 25  
Carrier gas Helium 
Injector PTV  100°C for 0.2 sec.; 14.5°C/sec. to 
300°C; 300°C for 5 min. 
Split flow (ml/min) 50  
GC-MS interface T (°C)  300 
Source temperature T (°C) 250 
Damping gas flow (ml/min) 1.5  
MicroScans nr. 2 
 
Trace Finder 3.0 was used for data acquisition and data processing. 
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Statistical calculations were performed using Excel software 
The selected ions used for quantification and the ISs are reported in Table 15. 
Table 30: GC-MS selected ions and retention times 
Analyte ID 
 Selected ions  
RT (min) Quan Mass Conf. Mass Internal Standard 
BHT-d21 8.25 222 240  
BHT 8.4 205 220 BHT-d21 
Triallate 11.93 268 270 p-terphenyl-d14 
p-terphenyl-d14 15.38 244 243  
EHMC 16.46 178 161 p-terphenyl-d14 
5 Preparation of calibration standards and water samples for 
LC-MS analysis 
5.1 Calibration standards and Quality Control samples (QCs) 
Corresponding water samples were produced by adding 0.01 ml of standard solutions A-E 
respectively in 1 l MilliQ water (calibration ranges as indicated in Table 2 ‘Studied 
calibration ranges’ in the report) and then spiked with 10 µl of IS working solution.  
5.2 Water sample extraction  
SPE OASIS HLB cartridges were conditioned with 10 ml methanol followed by 10 ml water. 
The water samples, spiked with 10 µl IS working solution, were loaded at 5 ml/min and 
successively the cartridges were dried under nitrogen for 30 minutes. The sorbent was 
eluted with 10 ml methanol (3 ml/minute), the eluent evaporated to dryness under a 
gentle stream of nitrogen and then reconstituted with 0.1 mL water: acetonitrile, 9:1, % 
v/v. 
6 Preparation of calibration standards and water samples for 
GC-MS analysis  
6.1 Calibration standards and Quality Control samples (QCs) 
Corresponding water samples were produced by adding 0.1 ml of standard solutions A-E 
respectively in 10 ml MilliQ water (calibration ranges as indicated in Table 2 ‘Studied 
calibration ranges’ in the report) in a 60 ml glass vial and then spiked with 0.1 ml of IS 
working solutions.  
 
6.2 Water sample extraction  
0.1 ml of BHT d21 and p-terphenyl d14 working solutions were added to 10 ml water 
samples which were then extracted twice with 10 ml hexane, using a horizontal shaking 
table. To the hexane extracts 0.1 ml toluene weas added as keeper and evaporated to 
approximately 0.1 ml. It is important that samples never reach complete dryness, as this 
will result in a complete loss of the BHT and Triallate.   
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1 Introduction 
The R code used for the ANCOVA analysis and the full R outputs are described below.  
ANCOVA was performed using the R software (R Core Team, 2014) with the following 
variables specifications: 
 Std, the covariate variable = the concentration of the standard solution used to 
compute the calibration curve. Five concentration levels were used; 
 Computed, the dependent variable = the computed concentration of the compound 
obtained from the peak area; 
 Day, the factor = the fixed factor which corresponds to the calibration day in cases 
a and b, and to the matrix type for case c. 
ANCOVA was performed to establish whether, for each level of the factor, all calibration 
curves have equal slopes and intercepts. This means verifying whether or not the factor 
has a significant effect on the dependent variable, ‘cleaned’ by the effect of the covariate 
variable. 
Depending on the case, the factor can have five, three or two levels. In case a, the five 
levels are given by the five different days on which the calibration curves are determined 
in MilliQ water. In case b, the three levels are the two calibration curves determined in 
surface water. In case c, the two levels correspond to the calibration curves determined 
in both MilliQ and surface water, after having verified the day-to-day stability of calibration 
curves in each water type separately. 
Null hypotheses 
The first null hypothesis of ANCOVA is that the slopes of the regression lines are all equal; 
in other words, the regression lines are parallel to each other. Once the null hypothesis of 
parallel regression lines is accepted, it is possible to test the second null hypothesis: the 
intercepts of the regression lines are all the same. 
2. Verification of the ANCOVA assumptions 
2.1. Independence 
The R code applied to each compound separately is the following: 
> independence<-aov(Std~Day, Data), 
> summary(independence). 
 
Full R outputs for this command are given in Table 31, 32 and 33 for MilliQ water, surface 
water and matrix comparison, respectively. 
Table 31: R output of the independence test for the MilliQ water 
Chemical R output – Case a: Milli-Q water 
17-α-Ethinyl 
estradiol 
 Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 4 0 0 0 1 
Residuals 25 36.17 1.447   
 
17-β-Estradiol  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 4 0 0 0 1 
Residuals 25 36.17 1.447   
 
Estrone  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
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Chemical R output – Case a: Milli-Q water 
Day 4 0 0 0 1 
Residuals 25 36.17 1.447   
 
Diclofenac  Df Sum Sq Mean 
Sq 
F 
value 
Pr(>F) 
Day 4 0 0 0 1 
Residuals 25 22604 904.2   
 
BHT  Df Sum Sq Mean Sq F 
value 
Pr(>F) 
Day 4 0 0 0 1 
Residuals 25 1.3e+07  5085938   
 
EHMC  Df Sum Sq Mean Sq F 
value 
Pr(>F) 
Day 4 0 0 0 1 
Residuals 25 55e+07 2.2e+07   
 
Clarythromycin  Df Sum Sq Mean 
Sq 
F 
value 
Pr(>F) 
Day 1 0 0 0 1 
Residuals 10 45764 4576   
 
Azythromycin  Df Sum Sq Mean 
Sq 
F 
value 
Pr(>F) 
Day 1 0 0 0 1 
Residuals 10 45764 4576   
 
Methiocarb  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 4 0 0 0 1 
Residuals 25 1413 56.5   
 
Acetamiprid  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 4 0 0 0 1 
Residuals 25 1157 46.28   
 
Clothianidin  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 4 0 0 0 1 
Residuals 25 1157 46.28   
 
Imidacloprid  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 4 0 0 0 1 
Residuals 25 1157 46.28   
 
Thiacloprid  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 4 0 0 0 1 
Residuals 25 1157 46.28   
 
Thiamethoxam  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 4 0 0 0 1 
Residuals 25 1157 46.28   
 
Oxadiazon  Df Sum Sq Mean 
Sq 
F 
value 
Pr(>F) 
Day 4 0 0 0 1 
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Chemical R output – Case a: Milli-Q water 
Residuals 25 109404 4376   
 
Triallate  Df Sum Sq Mean 
Sq 
F 
value 
Pr(>F) 
Day 4 0 0 0 1 
Residuals 25  6341882   253675   
 
Table 32: R output of the independence test for the surface water 
Chemical R output – Case b: lake water 
17-α-Ethinyl 
estradiol 
 Df Sum Sq Mean 
Sq 
F 
value 
Pr(>F) 
Day 2 0 0 0 1 
Residuals 15 0.6646 0.0443   
 
17-β-Estradiol  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 2 0 0 0 1 
Residuals 15 21.7 1.447   
 
Estrone  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 2 0 0 0 1 
Residuals 15 21.7 1.447   
 
Diclofenac  Df Sum Sq Mean 
Sq 
F 
value 
Pr(>F) 
Day 2 0 0 0 1 
Residuals 15 13563 904.2   
 
BHT  Df Sum Sq Mean Sq F 
value 
Pr(>F) 
Day 2 0 0 0 1 
Residuals 15 7.6e+07 5085938   
 
EHMC  Df Sum Sq Mean Sq F 
value 
Pr(>F) 
Day 2 0 0 0 1 
Residuals 15 3.3e+08 2.2e+07   
 
Clarythromycin  Df Sum Sq Mean 
Sq 
F 
value 
Pr(>F) 
Day 2 0 0 0 1 
Residuals 15 68646 4576   
 
Azythromycin  Df Sum Sq Mean 
Sq 
F 
value 
Pr(>F) 
Day 2 0 0 0 1 
Residuals 15 68646 4576   
 
Methiocarb  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 2 0 0 0 1 
Residuals 15 847.7 56.51   
 
Acetamiprid  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 2 0 0 0 1 
Residuals 15 694.2 46.28   
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Chemical R output – Case b: lake water 
Clothianidin  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 2 0 0 0 1 
Residuals 15 694.2 46.28   
 
Imidacloprid  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 2 0 0 0 1 
Residuals 15 694.2 46.28   
 
Thiacloprid  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 2 0 0 0 1 
Residuals 15 694.2 46.28   
 
Thiamethoxam  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 2 0 0 0 1 
Residuals 15 694.2 46.28   
 
Oxadiazon  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 2 0 0 0 1 
Residuals 15 65642 4376   
 
Triallate  Df Sum Sq Mean 
Sq 
F 
value 
Pr(>F) 
Day 2 0 0 0 1 
Residuals 15 3805129 253675   
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Table 33: R output of the independence test for the matrix comparison 
Chemical R output – Case c: Matric effect 
17-α-Ethinyl 
estradiol 
 Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 1 0 0 0 1 
Residuals 10 0.443 0.0443   
 
17-β-Estradiol  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 1 0 0 0 1 
Residuals 10 14.47 1.447   
 
Estrone  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 1 0 0 0 1 
Residuals 10 14.47 1.447   
 
Diclofenac  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 1 0 0 0 1 
Residuals 10 9042 904.2   
 
BHT  Df Sum Sq Mean Sq F 
value 
Pr(>F) 
Day 1 0 0 0 1 
Residuals 10 5.1e+07 5.1e+06   
 
EHMC  Df Sum Sq Mean Sq F 
value 
Pr(>F) 
Day 1 0 0 0 1 
Residuals 10 2.2e+08 2.2e+07   
 
Clarythromycin  Df Sum Sq Mean 
Sq 
F 
value 
Pr(>F) 
Day 1 0 0 0 1 
Residuals 10 45764 4576   
 
Azythromycin  Df Sum Sq Mean 
Sq 
F 
value 
Pr(>F) 
Day 1 0 0 0 1 
Residuals 10 45764 4576   
 
Methiocarb  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 1 0 0 0 1 
Residuals 10 565.1 56.51   
 
Acetamiprid  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 1 0 0 0 1 
Residuals 10 462.8 46.28   
 
Clothianidin  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 1 0 0 0 1 
Residuals 10 462.8 46.28   
 
Imidacloprid  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 1 0 0 0 1 
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Chemical R output – Case c: Matric effect 
Residuals 10 462.8 46.28   
 
Thiacloprid  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 1 0 0 0 1 
Residuals 10 462.8 46.28   
 
Thiamethoxam  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 1 0 0 0 1 
Residuals 10 449 44.9   
 
Oxadiazon  Df Sum 
Sq 
Mean 
Sq 
F 
value 
Pr(>F) 
Day 1 0 0 0 1 
Residuals 10 43762 4376   
 
Triallate  Df Sum Sq Mean 
Sq 
F 
value 
Pr(>F) 
Day 1 0 0 0 1 
Residuals 10 2536753 253675   
 
 
2.2. Normality 
QQ-plots are plotted by typing the following R code: 
> Res.lm = lm(Computed~Day*Std, Data) 
> plot(Res.lm, main=‘Thiamethoxam’) 
 
QQ-plots are given in Table 34, Table 35 and Table 36 for MilliQ water, surface water and 
matrix comparison respectively. 
Table 34: R output of the normality test for the MilliQ water 
QQ-plots — Case a: MilliQ water 
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QQ-plots — Case a: MilliQ water 
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QQ-plots — Case a: MilliQ water 
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QQ-plots — Case a: MilliQ water 
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Table 35: R output of the normality test for the surface water 
QQ-plots — Case b: surface water 
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QQ-plots — Case b: surface water 
  
  
  
 23/05/2016  
13 of 28 
Pages 
 
QQ-plots — Case b: surface water 
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Table 36: R output of the normality test for the Matrix comparison 
QQ-plots — Case c: matrix comparison 
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QQ-plots — Case c: matrix comparison 
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QQ-plots — Case c: matrix comparison 
  
  
 
 
2.3. Homogeneity of variance 
Levene’s test is used to verify this assumption. The R code for the Levene’s test is the 
following: 
> leveneTest(Computed~Day, Data) 
Full R output of Levene’s test is given Tables 37, 38 and 39 for MilliQ water, surface water 
and matrix comparison, respectively.  
Table 37: R output of the homogeneity of variance test for the MilliQ water 
Chemical R output — Case a: MilliQ water 
17-α-Ethinyl 
estradiol 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 4 6e-04 1 
 25   
 
17-β-Estradiol 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 4 6e-04 1 
 25   
 
Estrone Levene's Test for Homogeneity of Variance (centre = median) 
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Chemical R output — Case a: MilliQ water 
 Df F value Pr(>F) 
group 4 6e-04 1 
 25   
 
Diclofenac 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 4 0.0096 0.9998 
 23   
 
BHT 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 4 9e-04 1 
 25   
 
EHMC 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 4 0.005 0.9999 
 25   
 
Clarythromycin 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 1 0 0.9967 
 8   
 
Azythromycin 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 1 0 0.9973 
 8   
 
Methiocarb 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 4 0.0279 0.9984 
 22   
 
Acetamiprid 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 4 7e-04 1 
 25   
 
Clothianidin 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 4 7e-04 1 
 25   
 
Imidacloprid 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 4 4e-04 1 
 25   
 
Thiacloprid 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 4 5e-04 1 
 25   
 
Thiamethoxam 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 4 8e-04 1 
 25   
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Chemical R output — Case a: MilliQ water 
Oxadiazon 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 4 0.008 0.9999 
 21   
 
Triallate 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 4 0.0059 0.9999 
 25   
 
 
Table 38: R output of the homogeneity of variance test for the surface water 
Chemical R output – Case b: Surface water 
17-α-Ethinyl 
estradiol 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 2 0 1 
 15   
 
17-β-Estradiol 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 2 3e-04 0.9997 
 15   
 
Estrone 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 2 5e-04 0.9995 
 15   
 
Diclofenac 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 2 4e-04 0.9996 
 15   
 
BHT 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 2 3e-04 0.9997 
 15   
 
EHMC 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 2 0.0115 0.9886 
 15   
 
Clarythromycin 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 2 3e-04 0.9997 
 15   
 
Azythromycin 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 2 4e-04 0.9996 
 15   
 
Methiocarb 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
 23/05/2016  
19 of 28 
Pages 
 
Chemical R output – Case b: Surface water 
group 2 6e-04 0.9994 
 15   
 
Acetamiprid 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 2 4e-04 0.9996 
 15   
 
Clothianidin 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 2 2e-04 0.9998 
 15   
 
Imidacloprid 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 2 0.0021 0.998 
 15   
 
Thiacloprid 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 2 4e-04 0.9996 
 15   
 
Thiamethoxam 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 2 1e-04 0.9999 
 15   
 
Oxadiazon 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 2 0.4396 0.6529 
 14   
 
Triallate 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 2 0.004 0.996 
 15   
 
 
Table 39: R output of the homogeneity of variance test for the matrix comparison 
Chemical R output – Case c: Matrix comparison 
17-α-Ethinyl 
estradiol 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 1 2e-04 0.9899 
 10   
 
17-β-Estradiol 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 1 5e-04 0.9821 
 10   
 
Estrone 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 1 3e-04 0.986 
 10   
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Chemical R output – Case c: Matrix comparison 
Diclofenac 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 1 0.001 0.9757 
 10   
 
BHT 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 1 0.0012 0.9828 
 10   
 
EHMC 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 1 0.0195 0.8917 
 10   
 
Clarythromycin 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 1 0.0248 0.8784 
 9   
 
Azythromycin 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 1 0.0252 0.8774 
 9   
 
Methiocarb 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 1 1e-04 0.9907 
 10   
 
Acetamiprid 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 1 0.0016 0.9686 
 10   
 
Clothianidin 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 1 8e-04 0.9786 
 10   
 
Imidacloprid 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 1 0 0.9993 
 10   
 
Thiacloprid 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 1 3e-04 0.9868 
 10   
 
Thiamethoxam 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 1 6e-04 0.9815 
 10   
 
Oxadiazon 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 1 0.0016 0.9685 
 10   
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Chemical R output – Case c: Matrix comparison 
Triallate 
Levene's Test for Homogeneity of Variance (centre = median) 
 Df F value Pr(>F) 
group 1 2e-04 0.9899 
 10   
 
 
3. ANCOVA results 
3.1. R code explanation 
For brevity, the complete R code explanation is given only for the Triallate in the MilliQ 
water. For the other compounds and for the surface water and matrix comparison cases, 
full R outputs are expressed in a tabular format. 
In R, the ANCOVA model with five different slopes and five different intercepts (one per 
day) is specified using the following code: 
> model_1<-lm(Computed~Day*Std, Data) 
> summary(model) 
 
The R output is the following (Triallate in MilliQ water): 
Call: 
lm(formula = Computed ~ Day * Std, data = Data) 
 
Residuals: 
Min 1Q Median 3Q Max 
-53.011 -8.167 -0.100 12.167 40.245 
 
Coefficients: 
 Estimate Std. Error t value Pr(>|t|) 
(Intercept) -7.726029 14.021113 -0.551 0.588 
DayDay2 -10.838314 19.828849 -0.547 0.591 
DayDay3 8.679657 19.828849 0.438 0.666 
DayDay4 -4.979257 19.828849 -0.251 0.804 
DayDay5 -19.675286 19.828849 -0.992 0.333 
Std 1.017855 0.022207 45.834 <2e-16*** 
DayDay2:Std 0.002296 0.031406 0.073 0.942 
DayDay3:Std -0.01889 0.031406 -0.601 0.554 
DayDay4:Std 0.011508 0.031406 0.366 0.718 
DayDay5:Std 0.04547 0.031406 1.448 0.163 
 
--- 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
Residual standard 
error: 
25.01 on 20 degrees of 
freedom 
Multiple R-squared:  0.9981 
Adjusted R-squared:  0.9973 
F-statistic:  1186 on 9 and 20 DF 
p-value: < 2.2e-16 
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The model estimated 10 parameters from the data (10 rows in the R output): five 
intercepts and five slopes. The first day (day was the unit used as factor) is used as a 
baseline against which to compare the other four days. 
The coefficients -7.726029 (Intercept) and 1.017855 (Std) represent the intercept and the 
slope of the regression line for day 1. For the day 2, the intercept and the slope are given 
by the sum, respectively, of the first and second quantities (-7.726029 + -10.838314 = -
18.564343) and the sum of the sixth and seventh quantities (1.017855 +0.002296 
=1.020151). The other days’ regression parameters can be computed in the same way by 
summing the proper rows. 
The last column on the right indicates the parameter values which are significantly 
different from zero when compared with day 1. The table shows that intercepts (first five 
rows) and slopes (last five rows) do not differ significantly from day 1 at a level of 
significance of 95%. However, this model compares by a t-test, the slopes and the 
intercepts of different days, only with the slope and intercept for day 1. 
To test the hypothesis of equal slopes of regression lines for several days, the complete 
model containing the interaction term must be compared with the model for which the 
parallelism hypothesis is considered valid. The model with equal slope is given by: 
model_2 <- lm(Computed ~ Day + Std, Data) 
and the comparison is obtained with the R code: 
 
anova(model_1, model_2) 
The output of the ANOVA command is: 
Analysis of Variance Table 
 
Model 1: Computed ~ Day * Std 
Model 2: Computed ~ Day + Std 
 Res.Df RSS  Df Sum of Sq F Pr(>F) 
1 20 12510     
2 24 15346 -4 -2836 1.1334 0.369 
 
From the output, the p-value from the F test is higher than 0.05 (Pr=0.369) and the null 
hypothesis of equal slopes between the five regression lines is therefore accepted at 95 % 
level of confidence. At this point, it is possible to test the equality of the intercepts. This 
is done by comparing the previous model (equal slopes) with the model which assumes 
equal regression lines (equal slopes and equal intercepts). 
Model_3 <- lm(Computed ~ Std, Data) 
anova(model_2, model_3) 
 
The output is: 
Analysis of Variance Table 
 
Model 1: Computed ~ Day + Std 
Model 2: Computed ~ Std 
 Res.Df RSS Df Df Sum of Sq F Pr(>F) 
1 24 15346     
2 28 15825 -4 -478.38 0.187 0.940 
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Based on the results, the hypothesis of equals regression lines (Pr>>0.05) is accepted at 
95 % confidence level. This implies that the day at which the calibration curve is computed 
does not influence the output variable (concentration of the analyte). 
The same results can be obtained by a summary R code which results in an ANOVA table 
with the summary parameters: 
> model_B<-aov(Computed~Std*Day, Data) 
> summary(model_B) 
 
 Df Sum Sq Mean Sq F value Pr(>F) 
Day 1 6675059 6675059 10671.236 <2e-16 *** 
Std 4 478 120 0.191 0.940 
Day:Std 4 2836 709 1.133 0.369 
Residuals 20 12510 626   
  
--- 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
The F values and the corresponding probability values for the interaction term (Day:Std) 
and for the intercept (Day), are the same as found in the previous computations taken 
separately. Again, this indicates that there is no significant difference between the slopes 
and the intercepts of the calibration curves, at a level of confidence of 95%. 
This summary R code was used for all compound and results are given in the following 
section. 
 
3.2. R outputs 
This section reports the R output for the ANCOVA analysis in a tabular format. 
ANCOVA results for the MilliQ water are given in Table 40. 
ANCOVA results for the surface water are shown in Table 41 
ANCOVA results for the matric comparison (MilliQ water vs. surface water) are listed in 
Table 42. 
Table 40: ANCOVA output for the MilliQ water 
Chemical  D
f 
Sum Sq Mean Sq F value Pr(>F
) 
17-α-Ethinyl 
estradiol 
Std. 1 0.6928 0.6928 11033.834 <2e-
16*** Day 2 0.0000 0.0000 0.227 0.800 
Std:Da
y 
2 0.0000 0.0000 0.115 0.892 
Residu
al 
1
2 
0.0008 0.0001   
       
17-β-
Estradiol 
Std. 1 34.17 34.17 2947.521 <2e-
16*** Day 4 0.00 0.00 0.000 1.000 
Std:Da
y 
4 0.03 0.01 0.593 0.671 
Residu
al 
2
0 
0.23 0.01   
       
Estrone 
Std. 1 34.54 34.54 3193.043 <2e-
16*** Day 4 0.00 0.00 0.000 1.000 
Std:Da
y 
4 0.04 0.01 0.859 0.505 
Residu
al 
2
0 
0.22 0.01   
       Diclofenac Std. 1 21105 21105 3504.620 <2e-
16*** 
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Chemical  D
f 
Sum Sq Mean Sq F value Pr(>F
) Day 4 0 0 0.001 1.000 
Std:Da
y 
4 13 3 0.529 0.716 
Residu
al 
1
8 
108 6   
       
BHT 
Std. 1 1.39e+8 1,39e+8 9349.931 <2e-
16*** Day 4 0 0 0.000 1.000 
Std:Da
y 
4 102979 25745 1.729 0.183 
Residu
al 
2
0 
297885 14894   
       
EHMC 
Std. 1 6.59e+8 6,59e+8 1542.451 <2e-
16*** Day 4 51818 12955 0.030 0.998 
Std:Da
y 
4 3401002 850251 1.989 0.135 
Residu
al 
2
0 
8550328 427516   
       
Clarythromy
cin 
Std. 1 39797 39797 1669.929 1.44e-
08*** Day 1 0 0 0.000 0.990 
Std:Da
y 
1 0 0 0.004 0.954 
Residu
al 
6 143 24   
       
Azythromyci
n 
Std. 1 39250 39250 1313.927 2.9e-
08*** Day 1 0 0 0.001 0.973 
Std:Da
y 
1 2 2 0.055 0.822 
Residu
al 
6 179 30   
       
Methiocarb 
Std. 1 1379.4 1379.4 2669.363 <2e-
16*** Day 4 0.0 0.0 0.000 1.000 
Std:Da
y 
4 2.6 0.6 1.256 0.326 
Residu
al 
1
7 
8.8 0.5   
       
Acetamiprid 
Std. 1 1071.1 1071.1 3065.138 <2e-
16*** Day 4 0.0 0.0 0.001 1.000 
Std:Da
y 
4 0.2 0.1 0.147 0.962 
Residu
al 
2
0 
7.0 0.3   
       
Clothianidin 
Std. 1 1082.5 1082.5 4292.329 <2e-
16*** Day 4 0.0 0.0 0.000 1.000 
Std:Da
y 
4 0.1 0.0 0.093 0.984 
Residu
al 
2
0 
5.0 0.3   
       
Imidacloprid 
Std. 1 1080.4 1080.4 2474.859 <2e-
16*** Day 4 0.0 0.0 0.000 1.000 
Std:Da
y 
4 0.1 0.0 0.067 0.991 
Residu
al 
2
0 
8.7 0.4   
       
Thiacloprid 
Std. 1 1075.9 1075.9 3225.518 <2e-
16*** Day 4 0.0 0.0 0.000 1.000 
Std:Da
y 
4 0.1 0.0 0.099 0.982 
Residu
al 
2
0 
6.7 0.3   
       
Thiamethoxa
m 
Std. 1 1099.7 1099.7 5326.621 <2e-
16*** Day 4 0.0 0.0 0.001 1.00 
Std:Da
y 
4 0.2 0.1 0.292 0.88 
Residu
al 
2
0 
4.1 0.2   
       
Oxadiazon 
Std. 1 103195 103195 2660.957 <2e-
16 
*** 
Day 4 0 0 0.000 1.000 
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Chemical  D
f 
Sum Sq Mean Sq F value Pr(>F
) Std:Da
y 
4 122 30 0.784 0.552 
Residu
al 
1
6 
620 39   
       
Triallate 
Std. 4 478 120 0.191 0.940 
Day 1 6675059 6675059 10671.236 <2e-
16 
*** 
Std:Da
y 
4 2836 709 1.133 0.369 
Residu
al 
2
0 
12510 626   
       
Signif. codes: 0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
       
 
Table 41: ANCOVA output for the surface water 
Chemical  D
f 
Sum Sq Mean Sq F value Pr(>F
) 
17-α-Ethinyl 
estradiol 
Std. 1 0.6928 0.6928 11033.834 <2e-
16*** Day 2 0.0000 0.0000 0.227 0.800 
Std:Da
y 
2 0.0000 0.0000 0.115 0.892 
Residu
al 
1
2 
0.0008 0.0001   
       
17-β-
Estradiol 
Std. 1 21.016 21.016 6933.231 <2e-
16*** Day 2 0.000 0.000 0.001 0.999 
Std:Da
y 
2 0.006 0.003 0.926 0.423 
Residu
al 
1
2 
0.036 0.003   
       
Estrone 
Std. 1 21.070 21.070 7589.906 <2e-
16*** Day 2 0.000 0.000 0.001 0.999 
Std:Da
y 
2 0.000 0.000 0.078 0.925 
Residu
al 
1
2 
0.033 0.003   
       
Diclofenac 
Std. 1 13024 13024 2209.952 5.61e
-
15*** 
Day 2 0 0 0.001 0.999 
Std:Da
y 
2 2 1 0.171 0.845 
Residu
al 
1
2 
71 6   
       
BHT 
Std. 1 7.8e+07 7.8e+07 4989.278 <2e-
16*** Day 2 0 0 0.000 1.000 
Std:Da
y 
2 57879 28939 1.835 0.202 
Residu
al 
1
2 
189232 15769   
       
EHMC 
Std. 1 4.02e+08 4.02e+08 379.008 1.91e
-
10*** 
Day 2 30934 15467 0.015 0.986 
Std:Da
y 
2 3460239 1730120 1.630 0.236 
Residu
al 
1
2 
12733329 1061111   
       
Clarythromy
cin 
Std. 1 64284 64284 1469.963 6.38e
-
14*** 
Day 2 1 1 0.014 0.986 
Std:Da
y 
2 36 18 0.412 0.671 
Residu
al 
1
2 
525 44   
       
Azythromyci
n 
Std. 1 64929 64929 3475.074 3.75e
-
16*** 
Day 2 1 0 0.020 0.980 
Std:Da
y 
2 6 3 0.172 0.844 
Residu
al 
1
2 
224 19   
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Chemical  D
f 
Sum Sq Mean Sq F value Pr(>F
) 
Methiocarb 
Std. 1 845.4 845.4 2229.055 5.33e
-
15*** 
Day 2 0.0 0.0 0.019 0.981 
Std:Da
y 
2 0.5 0.3 0.712 0.510 
Residu
al 
1
2 
4.6 0.4   
       
Acetamiprid 
Std. 1 669.1 669.1 4414.498 <2e-
16*** Day 2 0.0 0.0 0.001 0.999 
Std:Da
y 
2 0.2 0.1 0.544 0.594 
Residu
al 
1
2 
1.8 0.2   
       
Clothianidin 
Std. 1 692.2 692.2 1.05e+07 <2e-
16*** Day 2 0.0 0.0 0.021 0.979 
Std:Da
y 
2 0.0 0.0 0.042 0.959 
Residu
al 
1
2 
0.8 0.1   
       
Imidacloprid 
Std. 1 663.9 663.9 5854.999 <2e-
16*** Day 2 0.1 0.1 0.480 0.630 
Std:Da
y 
2 0.4 0.2 1.543 0.253 
Residu
al 
1
2 
1.4 0.1   
       
Thiacloprid 
Std. 1 662.2 662.2 3024.195 8.61e
-
16*** 
Day 2 0.0 0.0 0.001 0.999 
Std:Da
y 
2 0.1 0.0 0.211 0.813 
Residu
al 
1
2 
2.6 0.2   
       
Thiamethoxa
m 
Std. 1 654.5 654.5 2407.473 3.37e
-
15*** 
Day 2 0.0 0.0 0.000 1.000 
Std:Da
y 
2 0.3 0.1 0.475 0.633 
Residu
al 
1
2 
3.3 0.3   
       
Oxadiazon 
Std. 1 49054 49054 1368.322 6.8e-
13*** Day 2 1 0 0.007 0.993 
Std:Da
y 
2 15 8 0.212 0.812 
Residu
al 
1
1 
394 36   
Triallate 
Std. 1 3878151 3878151 2279.886 4.66e
-
15*** 
Day 2 0 0 0.000 1.000 
Std:Da
y 
2 2600 1 300 0.764 0.487 
Residu
al 
1
2 
20412 1 701   
              
Signif. codes: 0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
 
Table 42: ANCOVA output for the matrix comparison 
Chemical  D
f 
Sum Sq Mean Sq F value Pr(>F
) 
17-α-Ethinyl 
estradiol 
Std. 1 0.4635 0.4635 2967.131 1.43e-
11*** Day 1 0.0000 0.0000 0.128 0.730 
Std:Da
y 
1 0.0000 0.0000 0.064 0.806 
Residu
al 
8 0.0012 0.0002   
       
17-β-
Estradiol 
Std. 1 13.925 13.925 5843.778 9.56e-
13*** Day 1 0.000 0.000 0.000 0.995 
Std:Da
y 
1 0.003 0.003 1.076 0.330 
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Chemical  D
f 
Sum Sq Mean Sq F value Pr(>F
) Residu
al 
8 0.019 0.002   
       
Estrone 
Std. 1 14.015 14.015 5218.700 1.5e-
12*** Day 1 0.000 0.000 0.002 0.970 
Std:Da
y 
1 0.000 0.000 0.001 0.979 
Residu
al 
8 0.021 0.003   
       
Diclofenac 
Std. 1 9039 9039 3739.214 5.69e-
12*** Day 1 0 0 0.000 0.987 
Std:Da
y 
1 0 0 0.035 0.857 
Residu
al 
8 19 2   
       
BHT 
Std. 1 5.2e+07 5.2e+07 6.326.330 6.96e-
13*** Day 1 0 0 0.000 1.000 
Std:Da
y 
1 677 677 0.081 0.783 
Residu
al 
8 66789 8349   
       
EHMC 
Std. 1 2.6e+08 2.6e+08 790.074 2.77e-
09*** Day 1 23201 23201 0.070 0.798 
Std:Da
y 
1 1120456 1120456 3.382 0.103 
Residu
al 
8 2650450 331306   
       
Clarythromyc
in 
Std. 1 42202 42202 2636.885 2.78e-
10*** Day 1 0 0 0.012 0.917 
Std:Da
y 
1 5 5 0.326 0.586 
Residu
al 
7 112 16   
       
Azythromyci
n 
Std. 1 418.7 418.7 1483.855 2.07e-
09*** Day 1 0.0 0.0 0.018 0.897 
Std:Da
y 
1 0.0 0.0 0.106 0.754 
Residu
al 
7 2.0 0.3   
       
Methiocarb 
Std. 1 571.0 571.0 1428.390 2.64e-
10*** Day 1 0.0 0.0 0.000 0.996 
Std:Da
y 
1 0.6 0.6 1.567 0.246 
Residu
al 
8 3.2 0.4   
       
Acetamiprid 
Std. 1 442.0 442.0 2373.772 3.48e-
11*** Day 1 0.0 0.0 0.000 0.984 
Std:Da
y 
1 0.1 0.1 0.585 0.466 
Residu
al 
8 1.5 0.2   
       
Clothianidin 
Std. 1 448.0 448.0 4991.4 1.79e-
12*** Day 1 0.0 0.0 0.0 0.993 
Std:Da
y 
1 0.2 0.2 1.7 0.229 
Residu
al 
8 0.7 0.1   
       
Imidacloprid 
Std. 1 437.1 437.1 1583.147 1.75e-
10*** Day 1 0.0 0.0 0.000 0.997 
Std:Da
y 
1 0.0 0.0 0.076 0.790 
Residu
al 
8 2.2 0.3   
       
Thiacloprid 
Std. 1 441.3 441.3 1771.310 1.12e-
10*** Day 1 0.0 0.0 0.001 0.978 
Std:Da
y 
1 0.0 0.0 0.013 0.911 
Residu
al 
8 2.0 0.2   
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Chemical D
f
Sum Sq Mean Sq F value Pr(>F
)
Thiamethoxa
m 
Std. 1 433.2 433.2 1461.782 2.41e-
10***Day 1 0.0 0.0 0.001 0.974 
Std:Da
y
1 0.0 0.0 0.114 0.744 
Residu
al
8 2.4 0.3 
 
Oxadiazon 
Std. 1 40106 40 106 724.802 3.9e-
09***Day 1 0 0 0.000 0.998 
Std:Da
y
1 4 4 0.073 0.794 
Residu
al
8 443 55 
 
Triallate 
Std. 1 2573223 2573223 4171.43 3.67e-
12***Day 1 0 0 0.00 1.000 
Std:Da
y
1 290 290 0.47 0.512 
Residu
al
8 4935 617 
 
Signif. codes: 0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
How to obtain EU publications 
Our publications are available from EU Bookshop (http://bookshop.europa.eu), 
where you can place an order with the sales agent of your choice. 
The Publications Office has a worldwide network of sales agents. 
You can obtain their contact details by sending a fax to (352) 29 29-42758. 
Europe Direct is a service to help you find answers to your questions about the European Union 
Free phone number (*): 00 800 6 7 8 9 10 11 
(*) Certain mobile telephone operators do not allow access to 00 800 numbers or these calls may be billed. 
A great deal of additional information on the European Union is available on the Internet. 
It can be accessed through the Europa server http://europa.eu 
23/05/2016 
2 of 1 
Pages 
doi:10.2788/85401 
ISBN 978-92-79-57556-3 
X
X
-N
A
-x
x
x
x
x
-E
N
-N
JRC Mission 
As the Commission’s  
in-house science service,  
the Joint Research Centre’s 
mission is to provide EU  
policies with independent,  
evidence-based scientific  
and technical support  
throughout the whole  
policy cycle. 
Working in close  
cooperation with policy  
Directorates-General,  
the JRC addresses key  
societal challenges while  
stimulating innovation  
through developing  
new methods, tools  
and standards, and sharing 
its know-how with  
the Member States,  
the scientific community  
and international partners. 
Serving society  
Stimulating innovation 
Supporting legislation 
L
B
-N
A
-2
7
8
1
3
-E
N
-N
 
